Immunology of Psoriasis

Annual Review of Immunology 32, 227-255

DOI: 10.1146/annurev-immunol-032713-120225

Citation Report

#	Article	IF	CITATIONS
1	Inhibition of Inflammatory and Proliferative Responses of Human Keratinocytes Exposed to the Sesquiterpene Lactones Dehydrocostuslactone and Costunolide. PLoS ONE, 2014, 9, e107904.	1.1	42
2	Structural basis of IL-23 antagonism by an Alphabody protein scaffold. Nature Communications, 2014, 5, 5237.	5.8	54
4	Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis – Xenograft model. Journal of Autoimmunity, 2014, 55, 63-72.	3.0	58
5	The role of human 6â€sulfo LacNAc dendritic cells (slanDCs) in autoimmunity and tumor diseases. JDDG - Journal of the German Society of Dermatology, 2014, 12, 874-879.	0.4	4
6	Effects of TNF-Alpha Inhibitors on Circulating Th17 Cells in Patients Affected by Severe Psoriasis. Drug Development Research, 2014, 75, S73-S76.	1.4	14
7	Specific roles for dendritic cell subsets during initiation and progression of psoriasis. EMBO Molecular Medicine, 2014, 6, 1312-1327.	3.3	92
8	IL-12-and IL-23 in health and disease. Cytokine and Growth Factor Reviews, 2014, 25, 415-421.	3.2	117
9	MicroRNA-223 and miR-143 are important systemic biomarkers for disease activity in psoriasis. Journal of Dermatological Science, 2014, 75, 133-139.	1.0	80
10	Telocyte dynamics in psoriasis. Journal of Cellular and Molecular Medicine, 2015, 19, 1504-1519.	1.6	56
11	BubbleGUM: automatic extraction of phenotype molecular signatures and comprehensive visualization of multiple Gene Set Enrichment Analyses. BMC Genomics, 2015, 16, 814.	1.2	69
12	Meta-analysis derived atopic dermatitis (MADAD) transcriptome defines a robust AD signature highlighting the involvement of atherosclerosis and lipid metabolism pathways. BMC Medical Genomics, 2015, 8, 60.	0.7	123
13	Proteogenomic analysis of psoriasis reveals discordant and concordant changes in mRNA and protein abundance. Genome Medicine, 2015, 7, 86.	3.6	80
14	Efficacy and Safety of Tripterygium wilfordii Hook F Versus Acitretin in Moderate to Severe Psoriasis Vulgaris. Chinese Medical Journal, 2015, 128, 443-449.	0.9	58
15	Defining Mononuclear Phagocyte Subset Homology Across Several Distant Warm-Blooded Vertebrates Through Comparative Transcriptomics. Frontiers in Immunology, 2015, 6, 299.	2.2	70
16	Possible Triggering Effect of Influenza Vaccination on Psoriasis. Journal of Immunology Research, 2015, 2015, 1-4.	0.9	59
17	Oral Curcumin (Meriva) Is Effective as an Adjuvant Treatment and Is Able to Reduce IL-22 Serum Levels in Patients with Psoriasis Vulgaris. BioMed Research International, 2015, 2015, 1-7.	0.9	93
18	The immunologic effects of estrogen on psoriasis: A comprehensive review. International Journal of Women's Dermatology, 2015, 1, 104-107.	1.1	18
19	Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci. Nature Communications, 2015, 6, 7001.	5.8	156

#	ARTICLE	IF	Citations
20	Transcriptional landscape of psoriasis identifies the involvement of IL36 and IL36RN. BMC Genomics, 2015, 16, 322.	1.2	69
22	Implantable synthetic cytokine converter cells with AND-gate logic treat experimental psoriasis. Science Translational Medicine, 2015, 7, 318ra201.	5 . 8	115
23	Chronic, not acute, skin-specific inflammation promotes thrombosis in psoriasis murine models. Journal of Translational Medicine, 2015, 13, 382.	1.8	25
24	Apremilast in the treatment of moderate-to-severe plaque psoriasis: results from the ESTEEM studies. Clinical Investigation, 2015, 5, 777-791.	0.0	1
25	Treatment of coexistent psoriasis and lupus erythematosus. Journal of the American Academy of Dermatology, 2015, 72, 253-260.	0.6	36
26	Laser capture microdissection followed by nextâ€generation sequencing identifies diseaseâ€related micro <scp>RNA</scp> changes in psoriatic skin that reflect systemic micro <scp>RNA</scp> changes in psoriasis. Experimental Dermatology, 2015, 24, 187-193.	1.4	61
27	Tofacitinib for the treatment of moderate-to-severe psoriasis. Expert Review of Clinical Immunology, 2015, 11, 443-455.	1.3	38
28	The translational revolution and use of biologics in patients with inflammatory skin diseases. Journal of Allergy and Clinical Immunology, 2015, 135, 324-336.	1.5	175
29	Modelling epidermis homoeostasis and psoriasis pathogenesis. Journal of the Royal Society Interface, 2015, 12, 20141071.	1.5	44
30	MicroRNAs in Skin Diseases. , 2015, , 177-205.		2
32	Interleukin-22: Immunobiology and Pathology. Annual Review of Immunology, 2015, 33, 747-785.	9.5	679
33	Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature, 2015, 521, 222-226.	13.7	185
34	Effects of adalimumab, etanercept and ustekinumab on the expression of psoriasin (S100A7) in psoriatic skin. Journal of Dermatological Science, 2015, 80, 38-44.	1.0	12
35	The immunogenetics of Psoriasis: A comprehensive review. Journal of Autoimmunity, 2015, 64, 66-73.	3.0	447
36	Ruxolitinib Attenuates Cutaneous Lupus Development in a Mouse Lupus Model. Journal of Investigative Dermatology, 2015, 135, 1912-1915.	0.3	29
37	Investigation of anti-inflammatory and anti-proliferative activities promoted by photoactivated cationic porphyrin. Photodiagnosis and Photodynamic Therapy, 2015, 12, 444-458.	1.3	13
38	Treating Psoriasis During Pregnancy: Safety and Efficacy of Treatments. American Journal of Clinical Dermatology, 2015, 16, 389-398.	3.3	22
39	Programmed death-ligand 1, 2 expressions are decreased in the psoriatic epidermis. Archives of Dermatological Research, 2015, 307, 531-538.	1.1	22

#	Article	IF	CITATIONS
40	Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and) Tj ETQq0	0 0 0 rgBT	/Overlock 10
41	The tongue as an excitable medium. New Journal of Physics, 2015, 17, 033049.	1.2	17
42	Dysbiosis and Staphylococcus aureus Colonization Drives Inflammation in Atopic Dermatitis. Immunity, 2015, 42, 756-766.	6.6	428
43	miRNAs in inflammatory skin diseases and their clinical implications. Expert Review of Clinical Immunology, 2015, 11, 467-477.	1.3	23
44	Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis. Journal of Allergy and Clinical Immunology, 2015, 136, 351-359.e1.	1.5	162
45	IL12/IL23 Inhibition in the Treatment of Psoriatic Arthritis. Current Treatment Options in Rheumatology, 2015, 1, 197-209.	0.6	3
46	Psoriasis drug development and GWAS interpretation through <i>in silico</i> analysis of transcription factor binding sites. Clinical and Translational Medicine, 2015, 4, 13.	1.7	40
47	Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. Journal of Allergy and Clinical Immunology, 2015, 136, 116-124.e7.	1.5	225
48	Glycyrrhizin Ameliorates Imiquimod-Induced Psoriasis-like Skin Lesions in BALB/c Mice and Inhibits TNF-a-Induced ICAM-1 Expression via NF-κB/MAPK in HaCaT Cells. Cellular Physiology and Biochemistry, 2015, 35, 1335-1346.	1.1	71
49	<scp>CCL</scp> 7 contributes to the <scp>TNF</scp> â€alphaâ€dependent inflammation of lesional psoriatic skin. Experimental Dermatology, 2015, 24, 522-528.	1.4	30
50	Immunologic Overlap of Helper T-Cell Subtypes 17 and 22 in Erythrodermic Psoriasis and Atopic Dermatitis. JAMA Dermatology, 2015, 151, 753.	2.0	72
51	Oral psoriasisâ€"a diagnostic dilemma: a report of two cases and a review of the literature. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2015, 120, e183-e189.	0.2	18
52	Therapeutic and immunomodulatory effects of glucosamine in combination with low-dose cyclosporine A in a murine model of imiquimod-induced psoriasis. European Journal of Pharmacology, 2015, 756, 43-51.	1.7	21
53	Identification of Thiostrepton as a Novel Inhibitor for Psoriasis-like Inflammation Induced by TLR7–9. Journal of Immunology, 2015, 195, 3912-3921.	0.4	22
54	Estimation of isoform expression in RNA-seq data using a hierarchical Bayesian model. Journal of Bioinformatics and Computational Biology, 2015, 13, 1542001.	0.3	4
55	Concept of Remission in Chronic Plaque Psoriasis. Journal of rheumatology Supplement, The, 2015, 93, 57-60.	2.2	15
56	llºBζ is a key driver in the development of psoriasis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E5825-33.	3.3	95
57	Dynamics and Transcriptomics of Skin Dendritic Cells and Macrophages in an Imiquimod-Induced, Biphasic Mouse Model of Psoriasis. Journal of Immunology, 2015, 195, 4953-4961.	0.4	72

#	ARTICLE	IF	Citations
58	The role of group IIF-secreted phospholipase A2 in epidermal homeostasis and hyperplasia. Journal of Experimental Medicine, 2015, 212, 1901-1919.	4.2	84
59	Anti-TNF-α monoclonal antibody reverses psoriasis through dual inhibition of inflammation and angiogenesis. International Immunopharmacology, 2015, 28, 731-743.	1.7	32
60	Circadian Gene Clock Regulates Psoriasis-Like Skin Inflammation in Mice. Journal of Investigative Dermatology, 2015, 135, 3001-3008.	0.3	57
61	Immunological Consequences of JAK Inhibition: Friend or Foe?. Current Hematologic Malignancy Reports, 2015, 10, 370-379.	1.2	84
62	Biomarkers of An Autoimmune Skin Diseaseâ€"Psoriasis. Genomics, Proteomics and Bioinformatics, 2015, 13, 224-233.	3.0	82
63	Disease specific signature of circulating miR-150-5p and miR-21-5p in myasthenia gravis patients. Journal of the Neurological Sciences, 2015, 356, 90-96.	0.3	56
64	An Integrative Approach to Biomarker Development in Psoriatic Arthritis. Journal of rheumatology Supplement, The, 2015, 93, 43-47.	2.2	1
65	T cell responses in psoriasis and psoriatic arthritis. Autoimmunity Reviews, 2015, 14, 286-292.	2.5	125
66	Nanomedicine-based drug targeting for psoriasis: potentials and emerging trends in nanoscale pharmacotherapy. Expert Opinion on Drug Delivery, 2015, 12, 635-652.	2.4	79
67	The Immunopathogenesis of Psoriasis. Dermatologic Clinics, 2015, 33, 13-23.	1.0	269
68	Innate Lymphoid Cells in the Skin. Journal of Investigative Dermatology, 2015, 135, 673-678.	0.3	68
69	Application of Bioinformatics Methodologies in the Fields of Skin Biology and Dermatology. , 0, , .		0
70	The IL-12/IL-23 Cytokine Family. , 2016, , 525-533.		1
71	Management of scalp psoriasis: current perspectives. Psoriasis: Targets and Therapy, 2016, 6, 33.	1.2	12
72	Recent advances in understanding psoriasis. F1000Research, 2016, 5, 770.	0.8	105
73	Animal Models of Autoimmunity., 2016,, 227-240.		2
74	T Helper Cell Subsets in Clinical Manifestations of Psoriasis. Journal of Immunology Research, 2016, 2016, 1-7.	0.9	82
75	Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis. Drug Design, Development and Therapy, 2016, 10, 1763.	2.0	26

#	Article	IF	CITATIONS
76	Inhibitors of Serine Proteases in Regulating the Production and Function of Neutrophil Extracellular Traps. Frontiers in Immunology, 2016, 7, 261.	2.2	49
77	Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?. International Journal of Molecular Sciences, 2016, 17, 217.	1.8	73
78	Molecular and Cellular Profiling of Scalp Psoriasis Reveals Differences and Similarities Compared to Skin Psoriasis. PLoS ONE, 2016, 11, e0148450.	1.1	33
79	Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis. PLoS ONE, 2016, 11, e0167757.	1.1	27
80	Nanotechnology-Based Nano-Bullets in Antipsoriatic Drug Delivery. , 2016, , 157-166.		4
81	Current knowledge on psoriasis and autoimmune diseases. Psoriasis: Targets and Therapy, 2016, 6, 7.	1.2	122
82	Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis: Targets and Therapy, 2016, Volume 6, 131-144.	1.2	51
83	CD19+ B cell subsets in the peripheral blood and skin lesions of psoriasis patients and their correlations with disease severity. Brazilian Journal of Medical and Biological Research, 2016, 49, e5374.	0.7	24
84	Impact of pregnancy and oestrogen on psoriasis and potential therapeutic use of selective oestrogen receptor modulators for psoriasis. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1085-1091.	1.3	18
85	PGRN Suppresses Inflammation and Promotes Autophagy in Keratinocytes Through the Wnt/ \hat{l}^2 -Catenin Signaling Pathway. Inflammation, 2016, 39, 1387-1394.	1.7	44
86	CD69 controls the uptake of L-tryptophan through LAT1-CD98 and AhR-dependent secretion of IL-22 in psoriasis. Nature Immunology, 2016, 17, 985-996.	7.0	98
87	IgE and Fcl̂µ <scp>RI</scp> are highly expressed on innate cells in psoriasis. British Journal of Dermatology, 2016, 175, 122-133.	1.4	17
88	Transgenic expression of human amphiregulin in mouse skin: inflammatory epidermal hyperplasia and enlarged sebaceous glands. Experimental Dermatology, 2016, 25, 187-193.	1.4	12
89	The singleâ€chain antiâ€ <scp>TNF</scp> â€ <i>α</i> antibody <scp>DLX</scp> 105 induces clinical and biomark responses upon local administration in patients with chronic plaqueâ€type psoriasis. Experimental Dermatology, 2016, 25, 428-433.	er 1.4	15
90	Monocyte-derived inflammatory Langerhans cells and dermal dendritic cells mediate psoriasis-like inflammation. Nature Communications, 2016, 7, 13581.	5.8	132
91	Programmed cell death ligand 1 alleviates psoriatic inflammation by suppressing IL-17A production from programmed cell death 1–high TÂcells. Journal of Allergy and Clinical Immunology, 2016, 137, 1466-1476.e3.	1.5	65
92	The Inflammatory Response in Psoriasis: a Comprehensive Review. Clinical Reviews in Allergy and Immunology, 2016, 50, 377-389.	2.9	284
93	Calcipotriol and betamethasone dipropionate exert additive inhibitory effects on the cytokine expression of inflammatory dendritic cell–Th17 cell axis in psoriasis. Journal of Dermatological Science, 2016, 81, 153-164.	1.0	57

#	Article	IF	CITATIONS
94	Myeloid-Derived Suppressor Cells in Psoriasis Are an Expanded Population Exhibiting Diverse T-Cell–Suppressor Mechanisms. Journal of Investigative Dermatology, 2016, 136, 1801-1810.	0.3	38
95	IL36RN Mutations Affect Protein ExpressionÂand Function: A Basis for Genotype-Phenotype Correlation in Pustular Diseases. Journal of Investigative Dermatology, 2016, 136, 1811-1819.	0.3	76
96	Gradual development of psoriatic skin lesions by constitutive low-level expression of IL-17A. Cellular Immunology, 2016, 308, 57-65.	1.4	12
97	OX40+ Regulatory T Cells in Cutaneous Squamous Cell Carcinoma Suppress Effector T-Cell Responses and Associate with Metastatic Potential. Clinical Cancer Research, 2016, 22, 4236-4248.	3.2	66
98	Treatment and management of psoriasis. Primary Health Care, 2016, 26, 32-41.	0.0	1
99	Targeting CD8+ T cells prevents psoriasis development. Journal of Allergy and Clinical Immunology, 2016, 138, 274-276.e6.	1.5	125
100	Oxidative stress in psoriasis and potential therapeutic use of antioxidants. Free Radical Research, 2016, 50, 585-595.	1.5	113
101	Calcitonin Gene–Related Peptide–Exposed Endothelial Cells Bias Antigen Presentation to CD4+ T Cells toward a Th17 Response. Journal of Immunology, 2016, 196, 2181-2194.	0.4	30
102	The Role of Adipocytes in Tissue Regeneration and Stem Cell Niches. Annual Review of Cell and Developmental Biology, 2016, 32, 609-631.	4.0	43
103	Keratinocytes contribute intrinsically to psoriasis upon loss of <i>Tnip1</i> function. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6162-E6171.	3.3	62
104	Distinctive downmodulation of plasmacytoid dendritic cell functions by vitamin D3 analogue calcipotriol. Journal of Dermatological Science, 2016, 84, 71-79.	1.0	9
105	The Roles of the Secreted Phospholipase A2 Gene Family in Immunology. Advances in Immunology, 2016, 132, 91-134.	1.1	64
106	Treatment of Skin Inflammation with Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated with Skin Inflammation and Skin Architecture Changes. Journal of Pharmacology and Experimental Therapeutics, 2016, 358, 413-422.	1.3	55
107	Pathophysiological basis of systemic treatments in psoriasis. JDDG - Journal of the German Society of Dermatology, 2016, 14, 557-572.	0.4	16
108	Decreased PD-1 positive blood follicular helper T cells in patients with psoriasis. Archives of Dermatological Research, 2016, 308, 593-599.	1.1	14
109	Psoriasis: Behind the scenes. Journal of Dermatology, 2016, 43, 4-8.	0.6	25
110	A randomized phase 2b trial of baricitinib, an oral Janus kinase (<scp>JAK</scp>) 1/JAK2 inhibitor, in patients with moderateâ€toâ€severe psoriasis. British Journal of Dermatology, 2016, 174, 1266-1276.	1.4	207
111	Topically Used Herbal Products for the Treatment of Psoriasis – Mechanism of Action, Drug Delivery, Clinical Studies. Planta Medica, 2016, 82, 1447-1455.	0.7	40

#	Article	IF	CITATIONS
112	Safety of secukinumab in the treatment of psoriasis. Expert Opinion on Drug Safety, 2016, 15, 1413-1420.	1.0	99
113	Macrophageâ€mediated psoriasis can be suppressed by regulatory T lymphocytes. Journal of Pathology, 2016, 240, 366-377.	2.1	44
114	MAD ointment ameliorates Imiquimod-induced psoriasiform dermatitis by inhibiting the IL-23/IL-17 axis in mice. International Immunopharmacology, 2016, 39, 369-376.	1.7	11
115	IL-12 protects from psoriasiform skin inflammation. Nature Communications, 2016, 7, 13466.	5.8	151
116	A PPARδ-selective antagonist ameliorates IMQ-induced psoriasis-like inflammation in mice. International Immunopharmacology, 2016, 40, 73-78.	1.7	9
117	Control of autoimmune inflammation by celastrol, a natural triterpenoid. Pathogens and Disease, 2016, 74, ftw059.	0.8	104
118	High throughput sequencing reveals the diversity of TRB-CDR3 repertoire in patients with psoriasis vulgaris. International Immunopharmacology, 2016, 40, 487-491.	1.7	17
119	NFATc1 supports imiquimod-induced skin inflammation by suppressing IL-10 synthesis in B cells. Nature Communications, 2016, 7, 11724.	5.8	46
120	New insights into the heterogeneity of Th17 subsets contributing to HIV-1 persistence during antiretroviral therapy. Retrovirology, 2016, 13, 59.	0.9	90
121	Understanding mechanisms of autoimmunity through translational research in vitiligo. Current Opinion in Immunology, 2016, 43, 81-88.	2.4	53
122	Pathophysiologische Grundlagen der Systemtherapien bei Psoriasis. JDDG - Journal of the German Society of Dermatology, 2016, 14, 557-573.	0.4	11
123	Signal transducer and activator of transcription 3 and vascular endothelial growth factor expression in psoriasis, an immunohistochemical study. Egyptian Journal of Pathology, 2016, 36, 229-234.	0.0	1
124	The paracaspase <scp>MALT</scp> 1 mediates <scp>CARD</scp> 14â€induced signaling in keratinocytes. EMBO Reports, 2016, 17, 914-927.	2.0	71
125	Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. New England Journal of Medicine, 2016, 375, 345-356.	13.9	670
126	Psoriasis mutations disrupt CARD14 autoinhibition promoting BCL10-MALT1-dependent NF-κB activation. Biochemical Journal, 2016, 473, 1759-1768.	1.7	62
127	Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity. Expert Review of Clinical Immunology, 2016, 12, 1299-1308.	1.3	67
128	Lipoprotein Metabolism and Inflammation in Patients With Psoriasis. American Journal of Cardiology, 2016, 118, 603-609.	0.7	30
130	Melanocytes in psoriasis: convicted culprit or bullied bystander?. Pigment Cell and Melanoma Research, 2016, 29, 261-263.	1.5	5

#	Article	IF	Citations
131	The Exonuclease Trex2 Shapes PsoriaticÂPhenotype. Journal of Investigative Dermatology, 2016, 136, 2345-2355.	0.3	15
132	New therapies for psoriasis and psoriatic arthritis. Current Opinion in Rheumatology, 2016, 28, 204-210.	2.0	60
133	Animal Models of Psoriasis and Psoriatic Arthritis. , 2016, , 103-109.		1
134	Functionalized gold nanoparticles for topical delivery of methotrexate for the possible treatment of psoriasis. Colloids and Surfaces B: Biointerfaces, 2016, 141, 141-147.	2.5	104
135	A case series of the effects of a novel composition of a traditional natural preparation for the treatment of psoriasis. Journal of Traditional and Complementary Medicine, 2016, 6, 395-398.	1.5	7
136	lîºBî¶: A key protein in the pathogenesis of psoriasis. Cytokine, 2016, 78, 20-21.	1.4	10
137	Inflammatory microenvironment and human papillomavirus-induced carcinogenesis. Cytokine and Growth Factor Reviews, 2016, 30, 103-111.	3.2	31
138	An Overview of the Pathogenesis of Immune-mediated Skin Injury. Toxicologic Pathology, 2016, 44, 536-544.	0.9	7
139	Increased Lipocalin-2 Contributes to the Pathogenesis of Psoriasis by Modulating Neutrophil Chemotaxis and Cytokine Secretion. Journal of Investigative Dermatology, 2016, 136, 1418-1428.	0.3	111
140	Treating psoriasis by targeting its susceptibility gene Rel. Clinical Immunology, 2016, 165, 47-54.	1.4	22
141	Astilbin inhibits Th17 cell differentiation and ameliorates imiquimod-induced psoriasis-like skin lesions in BALB/c mice via Jak3/Stat3 signaling pathway. International Immunopharmacology, 2016, 32, 32-38.	1.7	95
142	Cytokine Pathways in Psoriasis and Psoriatic Arthritis. , 2016, , 73-82.		4
143	IL-17A plays a central role in the expression of psoriasis signature genes through the induction of lκB-ζ in keratinocytes. International Immunology, 2016, 28, 443-452.	1.8	59
144	Psoriatic Arthritis and Psoriasis. , 2016, , .		3
145	Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis. Expert Opinion on Biological Therapy, 2016, 16, 255-263.	1.4	18
146	The tryptophan metabolism enzyme L-kynureninase is a novel inflammatory factor in psoriasis and other inflammatory diseases. Journal of Allergy and Clinical Immunology, 2016, 137, 1830-1840.	1.5	108
147	Update on psoriasis immunopathogenesis and targeted immunotherapy. Seminars in Immunopathology, 2016, 38, 11-27.	2.8	171
148	Molecular Phenotyping Small (Asian) versus Large (Western) Plaque Psoriasis Shows Common Activation of IL-17 Pathway Genes but Different Regulatory Gene Sets. Journal of Investigative Dermatology, 2016, 136, 161-172.	0.3	51

#	Article	IF	CITATIONS
149	Choroidal thickness in psoriasis. International Ophthalmology, 2017, 37, 173-177.	0.6	16
150	Immune cells from patients with psoriasis are defective in inducing indoleamine 2,3-dioxygenase expression in response to inflammatory stimuli. British Journal of Dermatology, 2017, 176, 695-704.	1.4	19
151	Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. British Journal of Dermatology, 2017, 176, 594-603.	1.4	55
152	Efficacy and safety of ustekinumab treatment in adults with moderateâ€toâ€severe atopic dermatitis. Experimental Dermatology, 2017, 26, 28-35.	1.4	182
153	The role of IL-4 in psoriasis. Expert Review of Clinical Immunology, 2017, 13, 171-173.	1.3	34
154	Psoriasis and Atopic Dermatitis. Dermatology and Therapy, 2017, 7, 31-41.	1.4	60
155	<scp>IL</scp> â€17A localizes in the exocytic compartment of mast cells in psoriatic skin. British Journal of Dermatology, 2017, 177, 1458-1460.	1.4	31
156	microRNA-130a Promotes Human Keratinocyte Viability and Migration and Inhibits Apoptosis Through Direct Regulation of STK40-Mediated NF-ΰB Pathway and Indirect Regulation of SOX9-Meditated JNK/MAPK Pathway: A Potential Role in Psoriasis. DNA and Cell Biology, 2017, 36, 219-226.	0.9	19
157	Noninvasive proteome analysis of psoriatic stratum corneum reflects pathophysiological pathways and is useful for drug profiling. British Journal of Dermatology, 2017, 177, 470-488.	1.4	28
158	CCN1 promotes IL- $1\hat{l}^2$ production in keratinocytes by activating p38 MAPK signaling in psoriasis. Scientific Reports, 2017, 7, 43310.	1.6	31
159	Psoriatic Arthritis. New England Journal of Medicine, 2017, 376, 957-970.	13.9	931
160	Dual Role of Act1 in Keratinocyte Differentiation and Host Defense: TRAF3IP2 Silencing Alters Keratinocyte Differentiation and Inhibits IL-17 Responses. Journal of Investigative Dermatology, 2017, 137, 1501-1511.	0.3	22
161	The role of IL 23 in the treatment of psoriasis. Expert Review of Clinical Immunology, 2017, 13, 525-534.	1.3	111
162	Vitamin D and its role in psoriasis: An overview of the dermatologist and nutritionist. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 195-205.	2.6	170
163	Endogenous Glucocorticoid Deficiency in Psoriasis Promotes Inflammation and Abnormal Differentiation. Journal of Investigative Dermatology, 2017, 137, 1474-1483.	0.3	38
164	Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial. Journal of Dermatology, 2017, 44, 873-884.	0.6	54
165	Paeonol ameliorates imiquimod-induced psoriasis-like skin lesions in BALB/c mice by inhibiting the maturation and activation of dendritic cells. International Journal of Molecular Medicine, 2017, 39, 1101-1110.	1.8	49
166	Incidence of autoimmune diseases in patients with scabies: a nationwide population-based study in Taiwan. Rheumatology International, 2017, 37, 1125-1134.	1.5	8

#	Article	IF	Citations
167	Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. New England Journal of Medicine, 2017, 376, 1551-1560.	13.9	413
168	Cutaneous Dendritic Cells in Health and Disease. , 2017, , 137-150.		0
169	Quercetin ameliorates imiquimod-induced psoriasis-like skin inflammation in mice via the NF-κB pathway. International Immunopharmacology, 2017, 48, 110-117.	1.7	98
170	Topically Delivered Tumor Necrosis Factor-α–Targeted Gene Regulation forÂPsoriasis. Journal of Investigative Dermatology, 2017, 137, 2027-2030.	0.3	22
171	Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis. Pharmacogenomics, 2017, 18, 631-638.	0.6	25
172	Cytokines and Chemokines. , 2017, , 239-264.		0
173	Investigating the potential of Oxymatrine as a psoriasis therapy. Chemico-Biological Interactions, 2017, 271, 59-66.	1.7	16
174	Immune-checkpoint protein VISTA critically regulates the IL-23/IL-17 inflammatory axis. Scientific Reports, 2017, 7, 1485.	1.6	68
175	Immunopathogenesis of Psoriasis. , 2017, , 373-395.		4
176	Th17 cell-mediated immune responses promote mast cell proliferation by triggering stem cell factor in keratinocytes. Biochemical and Biophysical Research Communications, 2017, 487, 856-861.	1.0	31
177	Psoriasis-Associated Late Cornified Envelope (LCE) Proteins Have AntibacterialÂActivity. Journal of Investigative Dermatology, 2017, 137, 2380-2388.	0.3	53
178	"Inflammatory skin march―in atopic dermatitis and psoriasis. Inflammation Research, 2017, 66, 833-842.	1.6	71
179	Anthralin modulates the expression pattern of cytokeratins and antimicrobial peptides by psoriatic keratinocytes. Journal of Dermatological Science, 2017, 87, 236-245.	1.0	12
180	Pathogenesis and immunotherapy in cutaneous psoriasis: what can rheumatologists learn?. Current Opinion in Rheumatology, 2017, 29, 71-78.	2.0	30
181	Interleukin 23 inhibitors for psoriasis: not just another number. Lancet, The, 2017, 390, 208-210.	6.3	7
182	Splicing factors differentially expressed in psoriasis alter mRNA maturation of disease-associated EDA+Afibronectin. Molecular and Cellular Biochemistry, 2017, 436, 189-199.	1.4	13
183	Tapinarof Is a Natural AhR Agonist thatÂResolves Skin Inflammation in MiceÂandÂHumans. Journal of Investigative Dermatology, 2017, 137, 2110-2119.	0.3	236
184	Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants. Nature Communications, 2017, 8, 15382.	5.8	251

#	Article	IF	CITATIONS
185	Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. British Journal of Dermatology, 2017, 177, 1014-1023.	1.4	155
186	Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors. European Journal of Immunology, 2017, 47, 1096-1107.	1.6	127
187	Psoriasis in patients with mycosis fungoides: a clinicopathological study of 25 patients. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1848-1852.	1.3	19
188	IL-17A causes depression-like symptoms via NFκB and p38MAPK signaling pathways in mice: Implications for psoriasis associated depression. Cytokine, 2017, 97, 14-24.	1.4	114
189	The nuclear factor (erythroidâ€derived 2)â€like 2 (<scp>NRF</scp> 2) antioxidant response promotes melanocyte viability and reduces toxicity of the vitiligoâ€inducing phenol monobenzone. Experimental Dermatology, 2017, 26, 637-644.	1.4	21
190	Synthetic Solutions to Drug Resistance. , 2017, , 595-608.		2
191	Overexpression of Drosha, DiGeorge syndrome critical region gene 8 (<scp>DGCR</scp> 8), and Dicer <scp>mRNA</scp> s in the pathogenesis of psoriasis. Journal of Cosmetic Dermatology, 2017, 16, e48-e53.	0.8	7
192	RIGâ€l antiviral signaling drives interleukinâ€23 production and psoriasisâ€like skin disease. EMBO Molecular Medicine, 2017, 9, 589-604.	3.3	46
193	Limited Presence of IL-22 Binding Protein, a Natural IL-22 Inhibitor, Strengthens Psoriatic Skin Inflammation. Journal of Immunology, 2017, 198, 3671-3678.	0.4	58
194	Drug Resistance in Bacteria, Fungi, Malaria, and Cancer., 2017,,.		13
196	Photodynamic effect of meso-(aryl)porphyrins and meso-(1-methyl-4-pyridinium)porphyrins on HaCaT keratinocytes. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 156-161.	1.0	25
197	CARD14-Mediated Activation of Paracaspase MALT1 in Keratinocytes: Implications for Psoriasis. Journal of Investigative Dermatology, 2017, 137, 569-575.	0.3	30
198	Activation of Langerhans cells promotes the inflammation in imiquimod-induced psoriasis-like dermatitis. Journal of Dermatological Science, 2017, 85, 170-177.	1.0	31
199	Calcipotriol Inhibits Proliferation of Human Keratinocytes by Downregulating Stat1 and Stat3 Signaling. Journal of Investigative Medicine, 2017, 65, 376-381.	0.7	10
200	Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies. Psychotherapy and Psychosomatics, 2017, 86, 260-267.	4.0	77
201	Oral Administration of Vanillin Improves Imiquimod-Induced Psoriatic Skin Inflammation in Mice. Journal of Agricultural and Food Chemistry, 2017, 65, 10233-10242.	2.4	25
202	C19, a C-terminal peptide of CKLF1, decreases inflammation and proliferation of dermal capillaries in psoriasis. Scientific Reports, 2017, 7, 13890.	1.6	7
203	Newer treatments of psoriasis regarding IL-23 inhibitors, phosphodiesterase 4 inhibitors, and Janus kinase inhibitors. Dermatologic Therapy, 2017, 30, e12555.	0.8	23

#	Article	IF	CITATIONS
204	An analysis of IL-36 signature genes and individuals with $\langle i \rangle$ IL1RL2 $\langle i \rangle$ knockout mutations validates IL-36 as a psoriasis therapeutic target. Science Translational Medicine, 2017, 9, .	5.8	124
205	Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis. Human Vaccines and Immunotherapeutics, 2017, 13, 2247-2259.	1.4	87
206	Revisiting murine models for atopic dermatitis and psoriasis with multipolar cytokine axes. Current Opinion in Immunology, 2017, 48, 99-107.	2.4	27
207	Signs of innate immune activation and premature immunosenescence in psoriasis patients. Scientific Reports, 2017, 7, 7553.	1.6	34
208	Atopic dermatitis and psoriasis: two different immune diseases or one spectrum?. Current Opinion in Immunology, 2017, 48, 68-73.	2.4	258
209	Unraveling Vascular Inflammation. Journal of the American College of Cardiology, 2017, 70, 1403-1412.	1.2	59
210	Psoriasis pathogenesis and the development of novel targeted immune therapies. Journal of Allergy and Clinical Immunology, 2017, 140, 645-653.	1.5	634
211	Controlling the pro-inflammatory function of 6-sulfo LacNAc (slan) dendritic cells with dimethylfumarate. Journal of Dermatological Science, 2017, 87, 278-284.	1.0	8
212	Increased frequencies of basophils, type 2 innate lymphoid cells and Th2 cells in skin of patients with atopic dermatitis but not psoriasis. Journal of Dermatological Science, 2017, 88, 167-174.	1.0	77
213	Trb3 is Elevated in Psoriasis Vulgaris Lesions and Mediates Hacat Cells Proliferation in Vitro. Journal of Investigative Medicine, 2017, 65, 1084-1088.	0.7	4
214	<scp>IL</scp> â€35 recombinant protein reverses inflammatory bowel disease and psoriasis through regulation of inflammatory cytokines and immune cells. Journal of Cellular and Molecular Medicine, 2018, 22, 1014-1025.	1.6	54
215	Screening of Skin Lesion-Associated Genes in Patients with Psoriasis by Meta-Integration Analysis. Dermatology, 2017, 233, 277-288.	0.9	5
216	The psoriasis-associated IL-17A induces and cooperates with IL-36 cytokines to control keratinocyte differentiation and function. Scientific Reports, 2017, 7, 15631.	1.6	94
217	The association of genetic variants in chemokine genes with the risk of psoriasis vulgaris in Chinese population. Medicine (United States), 2017, 96, e8283.	0.4	2
218	Sirolimus treatment for cirrhosis or hepatocellular carcinoma patients accompanied by psoriasis after liver transplantation: A single center experience. Oncology Letters, 2017, 14, 7817-7824.	0.8	7
219	Role of MyD88 signaling in the imiquimod-induced mouse model of psoriasis: focus on innate myeloid cells. Journal of Leukocyte Biology, 2017, 102, 791-803.	1.5	23
220	Unexplored diversity and strain-level structure of the skin microbiome associated with psoriasis. Npj Biofilms and Microbiomes, 2017, 3, 14.	2.9	159
221	The role of <scp>IL</scp> â€23 and the <scp>IL</scp> â€23/ <scp>T_H</scp> 17 immune axis in the pathogenesis and treatment of psoriasis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1616-1626.	1.3	187

#	Article	IF	Citations
222	n-3 polyunsaturated fatty acids supplementation in psoriasis: a review. Nutrire, 2017, 42, .	0.3	8
223	Efficacy and safety of ixekizumab treatment in Japanese patients with moderateâ€toâ€severe plaque psoriasis: Subgroup analysis of a placeboâ€controlled, phase 3 study (UNCOVERâ€1). Journal of Dermatology, 2017, 44, 1285-1290.	0.6	36
224	Induction of Alternative Proinflammatory Cytokines Accounts for Sustained Psoriasiform Skin Inflammation in IL-17C+IL-6KO Mice. Journal of Investigative Dermatology, 2017, 137, 696-705.	0.3	38
225	Proinflammatory effect of high-mobility group protein B1 onÂkeratinocytes: an autocrine mechanism underlying psoriasis development. Journal of Pathology, 2017, 241, 392-404.	2.1	38
226	Dimethyl―and monomethylfumarate regulate indoleamine 2,3â€dioxygenase (<scp>IDO</scp>) activity in human immune cells. Experimental Dermatology, 2017, 26, 685-690.	1.4	11
227	Adenosine A2A and A2B Receptors Differentially Modulate Keratinocyte Proliferation: Possible Deregulation in Psoriatic Epidermis. Journal of Investigative Dermatology, 2017, 137, 123-131.	0.3	24
228	Leptin deficiency in mice counteracts imiquimod (IMQ)â€induced psoriasisâ€like skin inflammation while leptin stimulation induces inflammation in human keratinocytes. Experimental Dermatology, 2017, 26, 338-345.	1.4	30
229	Modelling and finite-time stability analysis of psoriasis pathogenesis. International Journal of Control, 2017, 90, 1664-1677.	1.2	11
230	Sexy again: the renaissance of neutrophils in psoriasis. Experimental Dermatology, 2017, 26, 305-311.	1.4	71
231	MicroRNA-146a suppresses IL-17–mediated skin inflammation and is genetically associated with psoriasis. Journal of Allergy and Clinical Immunology, 2017, 139, 550-561.	1.5	107
232	Spread of Psoriasiform Inflammation to Remote Tissues Is Restricted by the Atypical Chemokine Receptor ACKR2. Journal of Investigative Dermatology, 2017, 137, 85-94.	0.3	28
233	Immunopathology alters Th17 cell glucocorticoid sensitivity. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 331-341.	2.7	38
234	Shrinking the Psoriasis Assessment Gap: Early Gene-Expression Profiling Accurately Predicts Response to Long-Term Treatment. Journal of Investigative Dermatology, 2017, 137, 305-312.	0.3	57
235	Keratinocyte-Derived Chemokines Orchestrate T-Cell Positioning in the Epidermis during Vitiligo and May Serve as Biomarkers of Disease. Journal of Investigative Dermatology, 2017, 137, 350-358.	0.3	132
236	Oral administration of a novel RORÎ ³ t antagonist attenuates psoriasis-like skin lesion of two independent mouse models through neutralization of IL-17. Journal of Dermatological Science, 2017, 85, 12-19.	1.0	35
237	Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis. Annual Review of Medicine, 2017, 68, 255-269.	5.0	134
238	Altered circulating T follicular helper cell subsets in patients with psoriasis vulgaris. Immunology Letters, 2017, 181, 101-108.	1.1	22
239	Dual Inhibition of PI3K/Akt and mTOR by the Dietary Antioxidant, Delphinidin, Ameliorates Psoriatic Features <i>In Vitro</i> and in an Imiquimod-Induced Psoriasis-Like Disease in Mice. Antioxidants and Redox Signaling, 2017, 26, 49-69.	2.5	71

#	Article	IF	CITATIONS
240	IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis. Clinical Immunology, 2017, 174, 63-72.	1.4	74
241	Psoriasis and Other Skin Inflammatory Diseases. , 2017, , 1091-1104.		1
242	RNA-seq identifies a diminished differentiation gene signature in primary monolayer keratinocytes grown from lesional and uninvolved psoriatic skin. Scientific Reports, 2017, 7, 18045.	1.6	37
243	New insight into the pathogenesis of nail psoriasis and overview of treatment strategies. Drug Design, Development and Therapy, 2017, Volume 11, 2527-2535.	2.0	44
244	Non-invasive monitoring of skin inflammation using an oxygen-sensing paint-on bandage. Biomedical Optics Express, 2017, 8, 4640.	1.5	20
245	Models in the Research Process of Psoriasis. International Journal of Molecular Sciences, 2017, 18, 2514.	1.8	82
246	The Immunogenetics of Psoriasis and Implications for Drug Repositioning. International Journal of Molecular Sciences, 2017, 18, 2650.	1.8	21
247	Resveratrol Role in Autoimmune Diseaseâ€"A Mini-Review. Nutrients, 2017, 9, 1306.	1.7	102
248	PRINS Non-Coding RNA Regulates Nucleic Acid-Induced Innate Immune Responses of Human Keratinocytes. Frontiers in Immunology, 2017, 8, 1053.	2.2	25
249	CD4 T-Cell Dysregulation in Psoriatic Arthritis Reveals a Regulatory Role for IL-22. Frontiers in Immunology, 2017, 8, 1403.	2.2	5
250	Natural Modulators of Endosomal Toll-Like Receptor-Mediated Psoriatic Skin Inflammation. Journal of Immunology Research, 2017, 2017, 1-15.	0.9	60
251	Clinical Efficiency of Topical Calcipotriol/Betamethasone Treatment in Psoriasis Relies on Suppression of the Inflammatory TNFα – IL-23 – IL-17 Axis. Acta Dermato-Venereologica, 2017, 97, 449-455.	0.6	13
252	Drug-induced psoriasis: clinical perspectives. Psoriasis: Targets and Therapy, 2017, Volume 7, 87-94.	1.2	72
253	Calcipotriene/betamethasone dipropionate for the treatment of psoriasis vulgaris: an evidence-based review. Clinical, Cosmetic and Investigational Dermatology, 2017, Volume 10, 385-391.	0.8	10
254	Author-paper affiliation network architecture influences the methodological quality of systematic reviews and meta-analyses of psoriasis. PLoS ONE, 2017, 12, e0175419.	1.1	6
255	GM-CSF in murine psoriasiform dermatitis: Redundant and pathogenic roles uncovered by antibody-induced neutralization and genetic deficiency. PLoS ONE, 2017, 12, e0182646.	1.1	11
256	Cardiovascular and Metabolic Diseases Comorbid with Psoriasis: Beyond the Skin. Internal Medicine, 2017, 56, 1613-1619.	0.3	49
257	Characterization of skin Th17 transcriptional profiles in psoriatic patients under adalimumab biotherapy. European Journal of Dermatology, 2017, 27, 579-589.	0.3	2

#	Article	IF	CITATIONS
258	Mast Cells and Microbiome in Skin Immunity. Journal of Bacteriology and Virology, 2017, 47, 165.	0.0	0
259	Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis. Psoriasis: Targets and Therapy, 2017, Volume 7, 65-72.	1.2	4
260	Single-center, noninterventional clinical trial to assess the safety, efficacy, and tolerability of a dimeticone-based medical device in facilitating the removal of scales after topical application in patients with psoriasis corporis or psoriasis capitis. Psoriasis: Targets and Therapy, 2017, Volume 7, 41-49.	1.2	1
261	The role of regulatory T cells and genes involved in their differentiation in pathogenesis of selected inflammatory and neoplastic skin diseases. Part II: The Treg role in skin diseases pathogenesis. Postepy Dermatologii I Alergologii, 2017, 5, 405-417.	0.4	32
262	Immunosuppressants for the Treatment of Psoriasis. Journal of the Nihon University Medical Association, 2017, 76, 31-35.	0.0	0
263	Underdiagnosed and undertreated psoriasis: Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatologic Therapy, 2018, 31, e12589.	0.8	95
264	Analysis of psoriasisâ€relevant gene expression and exon usage alterations after silencing of <scp>SR</scp> â€rich splicing regulators. Experimental Dermatology, 2018, 27, 656-662.	1.4	9
265	The contribution of feedback loops between miRNAs, cytokines and growth factors to the pathogenesis of psoriasis. Experimental Dermatology, 2018, 27, 603-610.	1.4	20
266	HIV-associated psoriasis. Actas Dermo-sifiliográficas, 2018, 109, 303-311.	0.2	7
267	Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis. Journal of the American Academy of Dermatology, 2018, 79, 345-352.	0.6	75
268	Neutralization of IL-17C Reduces Skin Inflammation in Mouse Models of Psoriasis and Atopic Dermatitis. Journal of Investigative Dermatology, 2018, 138, 1555-1563.	0.3	92
269	Eosinophils Accelerate Pathogenesis of Psoriasis by Supporting an Inflammatory Milieu that Promotes Neutrophil Infiltration. Journal of Investigative Dermatology, 2018, 138, 2185-2194.	0.3	24
270	High-Fat Diet Exacerbates Early Psoriatic Skin Inflammation Independent of Obesity: Saturated Fatty Acids as Key Players. Journal of Investigative Dermatology, 2018, 138, 1999-2009.	0.3	102
271	A review of the mechanisms of action of dimethylfumarate in the treatment of psoriasis. Experimental Dermatology, 2018, 27, 611-624.	1.4	94
272	Topical heat shock protein 70 prevents imiquimod-induced psoriasis-like inflammation in mice. Cell Stress and Chaperones, 2018, 23, 1129-1135.	1.2	17
273	Secukinumab treatment in newâ€onset psoriasis: aiming to understand the potential for disease modification – rationale and design of the randomized, multicenter <scp>STEPI</scp> n study. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1930-1939.	1.3	40
274	$TCR\hat{1}\pm\hat{1}^2+CD3+CD4~\hat{a}^2$ CD8 \hat{a}^2 (double negative) T cells in autoimmunity. Autoimmunity Reviews, 2018, 17, 422-430.	2.5	94
275	Autoinflammatory keratinization diseases: An emerging concept encompassing various inflammatory keratinization disorders of the skin. Journal of Dermatological Science, 2018, 90, 105-111.	1.0	65

#	Article	IF	CITATIONS
276	The Polycomb proteins RING1B and EZH2 repress the tumoral pro-inflammatory function in metastasizing primary cutaneous squamous cell carcinoma. Carcinogenesis, 2018, 39, 503-513.	1.3	18
277	Increased risk of psoriasis following scabies infection: A nationwide populationâ€based matchedâ€cohort study. Journal of Dermatology, 2018, 45, 302-308.	0.6	7
278	PI3K/AKT/mTOR activation and autophagy inhibition plays a key role in increased cholesterol during IL-17A mediated inflammatory response in psoriasis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1795-1803.	1.8	96
279	Psoriasis asociada al VIH. Actas Dermo-sifiliográficas, 2018, 109, 303-311.	0.2	14
280	Psoriasis: from Pathogenesis to Targeted Therapies. Clinical Reviews in Allergy and Immunology, 2018, 54, 102-113.	2.9	151
281	Structural Activation of Pro-inflammatory Human Cytokine IL-23 by Cognate IL-23 Receptor Enables Recruitment of the Shared Receptor IL- $12R\hat{l}^21$. Immunity, 2018, 48, 45-58.e6.	6.6	95
282	Skin-Specific CD301b+ Dermal Dendritic Cells Drive IL-17â^'Mediated Psoriasis-Like Immune Response in Mice. Journal of Investigative Dermatology, 2018, 138, 844-853.	0.3	31
283	Systemic inflammation in asocial BTBR T + tf/J mice predisposes them to increased psoriatic inflammation. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 83, 8-17.	2.5	35
284	PKCÎμÂpromotes human Th17 differentiation: Implications in the pathophysiology of psoriasis. European Journal of Immunology, 2018, 48, 644-654.	1.6	11
285	Genotypic variability-based genome-wide association study identifies non-additive loci HLA-C and IL12B for psoriasis. Journal of Human Genetics, 2018, 63, 289-296.	1.1	9
286	Highâ€fat diet exacerbates imiquimodâ€induced psoriasisâ€ike dermatitis in mice. Experimental Dermatology, 2018, 27, 178-184.	1.4	20
287	Autoimmunity and autoimmune coâ€morbidities in psoriasis. Immunology, 2018, 154, 21-27.	2.0	49
288	Durable Resolution of Severe Psoriasis in a Patient Treated with Pentostatin for Hairy Cell Leukemia: A Case Report. Dermatology and Therapy, 2018, 8, 165-169.	1.4	3
289	Genetically defined variants of toll-like receptors 3, 7 and 9 as phenotype and risk modifier factors for psoriasis. Journal of Dermatological Science, 2018, 89, 301-304.	1.0	0
290	Interleukin-17 Inhibition for the Treatment of Inflammatory Skin Disease. , 2018, , 133-144.		0
291	Janus Kinase Inhibitors. , 2018, , 187-198.		2
292	TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nature Communications, 2018, 9, 25.	5.8	194
293	Secukinumab shows high efficacy irrespective of <i>HLA-Cw6</i> status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. British Journal of Dermatology, 2018, 179, 1072-1080.	1.4	44

#	Article	IF	CITATIONS
294	SnapshotDx Quiz: April 2018. Journal of Investigative Dermatology, 2018, 138, e35.	0.3	0
295	Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment. Therapeutic Advances in Chronic Disease, 2018, 9, 111-119.	1.1	90
296	Decreased A-to-I RNA editing as a source of keratinocytes' dsRNA in psoriasis. Rna, 2018, 24, 828-840.	1.6	34
297	Transdermal immunomodulation: Principles, advances and perspectives. Advanced Drug Delivery Reviews, 2018, 127, 3-19.	6.6	70
298	Anti-IL-12/IL-23p40 antibody ameliorates dermatitis and skin barrier dysfunction in mice with imiquimod-induced psoriasis-like dermatitis. European Journal of Pharmacology, 2018, 828, 26-30.	1.7	14
299	p38α signaling in Langerhans cells promotes the development of IL-17–producing T cells and psoriasiform skin inflammation. Science Signaling, 2018, 11, .	1.6	20
300	Protein tyrosine phosphatase conjugated with a novel transdermal delivery peptide, astrotactin 1–derived peptide recombinant protein tyrosine phosphatase (AP-rPTP), alleviates both atopic dermatitis–like and psoriasis-like dermatitis. Journal of Allergy and Clinical Immunology, 2018, 141, 137-151.	1.5	15
301	dbGAPs: A comprehensive database of genes and genetic markers associated with psoriasis and its subtypes. Genomics, 2018, 110, 240-247.	1.3	4
302	Tofacitinib: A New Oral Therapy for Psoriasis. Clinical Drug Investigation, 2018, 38, 101-112.	1.1	23
303	Limitations of quantiferon-TB gold assay for screening of psoriasis patients prior to anti-tumour necrotic factor treatment. Infectious Diseases, 2018, 50, 317-319.	1.4	0
304	Inhibition of IL-17–committed T cells in a murine psoriasis model by a vitamin D analogue. Journal of Allergy and Clinical Immunology, 2018, 141, 972-981.e10.	1.5	22
305	CD100–Plexin-B2 Promotes the Inflammation in Psoriasis by Activating NF-κB and the Inflammasome inÂKeratinocytes. Journal of Investigative Dermatology, 2018, 138, 375-383.	0.3	58
306	The pruritogenic mediator endothelin†shifts the dendritic cell–Tâ€cell response toward Th17/Th1 polarization. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 511-515.	2.7	34
307	TNFα and ILâ€17A are differentially expressed in psoriasisâ€like vs eczemaâ€like drug reactions to TNFα antagonists. Journal of Cutaneous Pathology, 2018, 45, 23-28.	0.7	10
308	Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). British Journal of Dermatology, 2018, 178, 674-681.	1.4	80
309	Apremilast in psoriasis – a prospective realâ€world study. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 254-259.	1.3	54
310	Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis. American Journal of Clinical Dermatology, 2018, 19, 209-222.	3.3	39
311	Bclâ€3 induced by ILâ€22 via STAT3 activation acts as a potentiator of psoriasisâ€related gene expression in epidermal keratinocytes. European Journal of Immunology, 2018, 48, 168-179.	1.6	31

#	Article	IF	Citations
312	Pathogenesis of psoriasis and development of treatment. Journal of Dermatology, 2018, 45, 264-272.	0.6	309
313	Mouse models of psoriasis and their relevance. Journal of Dermatology, 2018, 45, 252-263.	0.6	41
314	Characterization of CD 45 RO + memory T lymphocytes in keloid disease. British Journal of Dermatology, 2018, 178, 940-950.	1.4	34
315	Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis. Pharmacogenomics, 2018, 19, 7-16.	0.6	21
316	Towards topical microRNA-directed therapy for epidermal disorders. Journal of Controlled Release, 2018, 269, 136-147.	4.8	32
317	Correlation of T cell and IL-17+ cell subsets in lesional skin of different subtypes of psoriasis. European Journal of Dermatology, 2018, 28, 401-403.	0.3	1
319	Systematic screening and identification of novel psoriasis‑specific genes from the transcriptome of psoriasis‑like keratinocytes. Molecular Medicine Reports, 2018, 19, 1529-1542.	1.1	7
320	Establishing the Initial Stage of Psoriasis in Cell Culture. Proceedings (mdpi), 2018, 2, .	0.2	0
321	Examining the epidemiology of coincident psoriasis and sarcoidosis: An observational cross-sectional study. Journal of the American Academy of Dermatology, 2018, , .	0.6	1
322	The epithelial immune microenvironment (EIME) in atopic dermatitis and psoriasis. Nature Immunology, 2018, 19, 1286-1298.	7.0	239
323	Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis. Drug Design, Development and Therapy, 2018, Volume 12, 3879-3883.	2.0	49
324	Coexistence of Kaposi's sarcoma and psoriasis: is there a hidden relationship?. European Journal of Dermatology, 2018, 28, 320-325.	0.3	6
325	Involvement of M1 Macrophage Polarization in Endosomal Toll-Like Receptors Activated Psoriatic Inflammation. Mediators of Inflammation, 2018, 2018, 1-14.	1.4	52
326	Integrating the skin and blood transcriptomes and serum proteome in hidradenitis suppurativa reveals complement dysregulation and a plasma cell signature. PLoS ONE, 2018, 13, e0203672.	1.1	71
327	Comparison of normal versus imiquimod-induced psoriatic skin in mice for penetration of drugs and nanoparticles. International Journal of Nanomedicine, 2018, Volume 13, 5625-5635.	3.3	26
328	Connective Tissue Growth Factor Neutralization Aggravates the Psoriasis Skin Lesion: The Analysis of Psoriasis Model Mice and Patients. Annals of Dermatology, 2018, 30, 47.	0.3	3
329	An Anti-Inflammatory Azaphenothiazine Inhibits Interferon \hat{l}^2 Expression and CXCL10 Production in KERTr Cells. Molecules, 2018, 23, 2443.	1.7	5
330	The Role of CXCR3 and Its Chemokine Ligands in Skin Disease and Cancer. Frontiers in Medicine, 2018, 5, 271.	1.2	123

#	Article	IF	CITATIONS
331	Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: case series and review of the literature. Clinical, Cosmetic and Investigational Dermatology, 2018, Volume 11, 451-459.	0.8	10
332	No increased risk of psoriasis in patients receiving androgen deprivation therapy for prostate cancer: a 17-year population-based study. Therapeutics and Clinical Risk Management, 2018, Volume 14, 1831-1837.	0.9	3
333	IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment. Cell Death and Disease, 2018, 9, 1104.	2.7	104
334	A role of IL-25, a sibling of IL-17, in triggering psoriatic skin inflammation. Science China Life Sciences, 2018, 61, 1437-1438.	2.3	1
335	Tofacitinib Represses the Janus Kinase-Signal Transducer and Activators of Transcription Signalling Pathway in Keratinocytes. Acta Dermato-Venereologica, 2018, 98, 772-775.	0.6	11
336	Alteration of the cutaneous microbiome in psoriasis and potential role in Th17 polarization. Microbiome, 2018, 6, 154.	4.9	190
337	ÎκBζ is a key transcriptional regulator of IL-36–driven psoriasis-related gene expression in keratinocytes. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 10088-10093.	3.3	89
338	Aromatic-turmerone ameliorates imiquimod-induced psoriasis-like inflammation of BALB/c mice. International Immunopharmacology, 2018, 64, 319-325.	1.7	40
339	The level of proinflammatory cytokines: interleukins 12, 23, 17 and tumor necrosis factor in patients with metabolic syndrome accompanying severe psoriasis and psoriatic arthritis. Postepy Dermatologii I Alergologii, 2018, 35, 360-366.	0.4	25
340	<i>UCHL1</i> /PGP 9.5 Dynamic in Neuro-Immune-Cutaneous Milieu: Focusing on Axonal Nerve Terminals and Epidermal Keratinocytes in Psoriatic Itch. BioMed Research International, 2018, 2018, 1-13.	0.9	9
341	Differential efficacy of biologic treatments targeting the TNF- \hat{l}_{\pm} /IL-23/IL-17 axis in psoriasis and psoriatic arthritis. Cytokine, 2018, 111, 182-188.	1.4	60
342	Chronotherapy of maxacalcitol on skin inflammation induced by topical 12- <i>O</i> -tetradecanoylphorbol-13-acetate in mice. Chronobiology International, 2018, 35, 1269-1280.	0.9	8
343	Psoriasis: a novel risk factor for type 2 diabetes. Lancet Diabetes and Endocrinology, the, 2018, 6, 919-921.	5.5	12
344	Interferon regulatory factor 5 and nuclear factor kappaâ€B exhibit cooperating but also divergent roles in the regulation of proâ€inflammatory cytokines important for the development of <scp>TH</scp> 1 and <scp>TH</scp> 17 responses. FEBS Journal, 2018, 285, 3097-3113.	2.2	19
345	MiRâ€126 correlates with increased disease severity and promotes keratinocytes proliferation and inflammation while suppresses cells' apoptosis in psoriasis. Journal of Clinical Laboratory Analysis, 2018, 32, e22588.	0.9	21
346	Integrative methylome and transcriptome analysis to dissect key biological pathways for psoriasis in Chinese Han population. Journal of Dermatological Science, 2018, 91, 285-291.	1.0	20
347	Nanoparticle-Assisted Transcutaneous Delivery of a Signal Transducer and Activator of Transcription 3-Inhibiting Peptide Ameliorates Psoriasis-like Skin Inflammation. ACS Nano, 2018, 12, 6904-6916.	7.3	46
348	Thyroid diseases and skin autoimmunity. Reviews in Endocrine and Metabolic Disorders, 2018, 19, 311-323.	2.6	22

#	Article	IF	CITATIONS
349	Gain-of-Function Mutation of Card14 Leads to Spontaneous Psoriasis-like Skin Inflammation through Enhanced Keratinocyte Response to IL-17A. Immunity, 2018, 49, 66-79.e5.	6.6	109
350	Influence of Adalimumab on the Expression Profile of Genes Associated with the Histaminergic System in the Skin Fibroblasts In Vitro. BioMed Research International, 2018, 2018, 1-11.	0.9	13
351	Chitosan-based nanoformulated (–)-epigallocatechin-3-gallate (EGCG) modulates human keratinocyte-induced responses and alleviates imiquimod-induced murine psoriasiform dermatitis. International Journal of Nanomedicine, 2018, Volume 13, 4189-4206.	3.3	54
352	Thymic Stromal Lymphopoietin Isoforms, Inflammatory Disorders, and Cancer. Frontiers in Immunology, 2018, 9, 1595.	2.2	133
353	East Indian Sandalwood Oil Is a Phosphodiesterase Inhibitor: A New Therapeutic Option in the Treatment of Inflammatory Skin Disease. Frontiers in Pharmacology, 2018, 9, 200.	1.6	15
354	Diabetes and the Skin. Endocrinology, 2018, , 1-15.	0.1	0
355	The distinct role and regulatory mechanism of IL-17 and IFN- \hat{I}^3 in the initiation and development of plaque vs guttate psoriasis. Journal of Dermatological Science, 2018, 92, 106-113.	1.0	16
356	Sex-Specific Cardiovascular Comorbidities with Associations in Dermatologic and Rheumatic Disorders. Advances in Experimental Medicine and Biology, 2018, 1065, 489-509.	0.8	5
357	Highlighting Interleukin-36 Signalling in Plaque Psoriasis and Pustular Psoriasis. Acta Dermato-Venereologica, 2018, 98, 5-13.	0.6	81
358	Synergistic cytokine effects as apremilast response predictors in patients with psoriasis. Journal of Allergy and Clinical Immunology, 2018, 142, 1010-1013.e6.	1.5	27
359	The Interplay Between Keratinocytes and Immune Cells in the Pathogenesis of Psoriasis. Frontiers in Immunology, 2018, 9, 1549.	2.2	279
360	PSORI-CM02 Formula Increases CD4+ Foxp3+ Regulatory T Cell Frequency and Ameliorates Imiquimod-Induced Psoriasis in Mice. Frontiers in Immunology, 2017, 8, 1767.	2.2	29
361	Langerhans Cells: Sensing the Environment in Health and Disease. Frontiers in Immunology, 2018, 9, 93.	2.2	141
362	IL-36γ Is a Strong Inducer of IL-23 in Psoriatic Cells and Activates Angiogenesis. Frontiers in Immunology, 2018, 9, 200.	2.2	58
363	MAPK Phosphatase-1 Deficiency Exacerbates the Severity of Imiquimod-Induced Psoriasiform Skin Disease. Frontiers in Immunology, 2018, 9, 569.	2.2	15
364	Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences. Frontiers in Immunology, 2018, 9, 579.	2.2	201
365	Potential Immunological Links Between Psoriasis and Cardiovascular Disease. Frontiers in Immunology, 2018, 9, 1234.	2.2	43
366	The Interleukin-23/Interleukin-17 Axis Links Adaptive and Innate Immunity in Psoriasis. Frontiers in Immunology, 2018, 9, 1323.	2.2	171

#	Article	IF	CITATIONS
367	T Cell Hierarchy in the Pathogenesis of Psoriasis and Associated Cardiovascular Comorbidities. Frontiers in Immunology, 2018, 9, 1390.	2.2	70
368	Pivotal Role of IL-22 Binding Protein in the Epithelial Autoregulation of Interleukin-22 Signaling in the Control of Skin Inflammation. Frontiers in Immunology, 2018, 9, 1418.	2.2	36
369	Foxp3+ T reg cells control psoriasiform inflammation by restraining an IFN-l–driven CD8+ T cell response. Journal of Experimental Medicine, 2018, 215, 1987-1998.	4.2	50
370	Serum of Patients with Psoriasis Modulates the Production of MMP-9 and TIMP-1 in Cells of Monocytic Lineage. Immunological Investigations, 2018, 47, 725-734.	1.0	10
371	Psoriasis: A STAT3-Centric View. International Journal of Molecular Sciences, 2018, 19, 171.	1.8	146
372	Scanning the Immunopathogenesis of Psoriasis. International Journal of Molecular Sciences, 2018, 19, 179.	1.8	212
373	Abnormal Sphingolipid World in Inflammation Specific for Lysosomal Storage Diseases and Skin Disorders. International Journal of Molecular Sciences, 2018, 19, 247.	1.8	28
374	Increased risk of incident psoriasis in endâ€stage renal disease patients on chronic hemodialysis: A nationwide populationâ€based cohort study. Journal of Dermatology, 2018, 45, 1063-1070.	0.6	12
375	MicroRNA-17-92 cluster promotes the proliferation and the chemokine production of keratinocytes: implication for the pathogenesis of psoriasis. Cell Death and Disease, 2018, 9, 567.	2.7	42
376	Three cases of facial erythema with dryness and pruritus in psoriasis patients during treatment with <scp>lL</scp> â€17 inhibitors. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e122-e123.	1.3	10
377	Thromboxane A 2 facilitates IL-17A production from $V\hat{l}^34 + \hat{l}^3\hat{l}'T$ cells and promotes psoriatic dermatitis in mice. Journal of Allergy and Clinical Immunology, 2018, 142, 680-683.e2.	1.5	39
378	The psoriasis-protective TYK2 I684S variant impairs IL-12 stimulated pSTAT4 response in skin-homing CD4+ and CD8+ memory T-cells. Scientific Reports, 2018, 8, 7043.	1.6	28
379	Epigenome-wide DNA methylation regulates cardinal pathological features of psoriasis. Clinical Epigenetics, 2018, 10, 108.	1.8	72
380	Pharmacokinetics of tazarotene and acitretin in psoriasis. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 919-927.	1.5	27
381	Understanding the prospective of nano-formulations towards the treatment of psoriasis. Biomedicine and Pharmacotherapy, 2018, 107, 447-463.	2.5	97
382	Restoration of CD3+CD56+ cell level improves skin lesions in severe psoriasis: A pilot clinical study of adoptive immunotherapy for patients with psoriasis using autologous cytokine-induced killer cells. Cytotherapy, 2018, 20, 1155-1163.	0.3	5
383	The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clinical Reviews in Allergy and Immunology, 2018, 55, 379-390.	2.9	447
384	Tildrakizumab for the treatment of psoriasis. Immunotherapy, 2018, 10, 1105-1122.	1.0	7

#	Article	IF	CITATIONS
385	SEB Stimulation Induces Functional Pathogenic Features in Th17 Cells from Psoriasis Patients. Journal of Investigative Dermatology, 2018, 138, 2677-2681.	0.3	2
386	The differential impact of scientific quality, bibliometric factors, and social media activity on the influence of systematic reviews and meta-analyses about psoriasis. PLoS ONE, 2018, 13, e0191124.	1.1	18
387	Evidence of curcumin and curcumin analogue effects in skin diseases: A narrative review. Journal of Cellular Physiology, 2019, 234, 1165-1178.	2.0	113
388	Paradoxical eczematous reaction to ixekizumab. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e40-e42.	1.3	21
389	Biologics for the primary care physician: Review and treatment of psoriasis. Disease-a-Month, 2019, 65, 51-90.	0.4	62
390	Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet, The, 2019, 394, 831-839.	6.3	250
391	Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderateâ€toâ€severe psoriasis: a pooled analysis of two randomized controlled trials. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 2305-2312.	1.3	40
392	Adaptive and Innate Immunity in Psoriasis and Other Inflammatory Disorders. Frontiers in Immunology, 2019, 10, 1764.	2.2	129
393	Selenium nanoparticles induce autophagy mediated cell death in human keratinocytes. Nanomedicine, 2019, 14, 1991-2010.	1.7	19
394	Organization of the Skin Immune System and Compartmentalized Immune Responses in Infectious Diseases. Clinical Microbiology Reviews, 2019, 32, .	5.7	74
395	Cutaneous p38 mitogen-activated protein kinase activation triggers psoriatic dermatitis. Journal of Allergy and Clinical Immunology, 2019, 144, 1036-1049.	1.5	37
396	Evaluation of selected mechanisms of immune tolerance in psoriasis. Postepy Dermatologii I Alergologii, 2019, 36, 319-328.	0.4	14
397	Analysis of factors predisposing to the occurrence of psoriasis among patients qualified for cyclosporine A therapy – a pilot study. Przeglad Dermatologiczny, 2019, 106, 225-228.	0.0	0
398	An Update on the Role of Adipose Tissues in Psoriasis. Frontiers in Immunology, 2019, 10, 1507.	2.2	39
399	Anti-inflammatory effect of naringin and sericin combination on human peripheral blood mononuclear cells (hPBMCs) from patient with psoriasis. BMC Complementary and Alternative Medicine, 2019, 19, 168.	3.7	35
400	IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis. Journal of Allergy and Clinical Immunology, 2019, 144, 750-763.	1.5	104
401	The Significance of IL-36 Hyperactivation and IL-36R Targeting in Psoriasis. International Journal of Molecular Sciences, 2019, 20, 3318.	1.8	91
402	Disrupting the IL-36 and IL-23/IL-17 loop underlies the efficacy of calcipotriol and corticosteroid therapy for psoriasis. JCl Insight, 2019, 4, .	2.3	34

#	Article	IF	CITATIONS
403	Increased frequency of activated CD8+ T cell effectors in patients with psoriatic arthritis. Scientific Reports, 2019, 9, 10870.	1.6	48
404	Immunolocalization of MUC1 in chronic plaque psoriasis. Journal of Immunoassay and Immunochemistry, 2019, 40, 515-527.	0.5	0
405	Macrophage S1PR1 Signaling Alters Angiogenesis and Lymphangiogenesis During Skin Inflammation. Cells, 2019, 8, 785.	1.8	16
406	On a Third-Order Singular Arc of Optimal Control in a Minimization Problem for a Mathematical Model of Psoriasis Treatment. Proceedings of the Steklov Institute of Mathematics, 2019, 304, 281-291.	0.1	3
407	Differential occurrence of lysine 2-hydroxyisobutyrylation in psoriasis skin lesions. Journal of Proteomics, 2019, 205, 103420.	1.2	18
408	Mannanâ€binding lectin promotes keratinocyte to produce CXCL1 and enhances neutrophil infiltration at the early stages of psoriasis. Experimental Dermatology, 2019, 28, 1017-1024.	1.4	12
409	Next-Generation Sequencing Identifies the Keratinocyte-Specific miRNA Signature of Psoriasis. Journal of Investigative Dermatology, 2019, 139, 2547-2550.e12.	0.3	21
410	Psoriatic and psoriatic arthritis patients with and without jet-lag: does it matter for disease severity scores? Insights and implications from a pilot, prospective study. Chronobiology International, 2019, 36, 1733-1740.	0.9	15
411	The cytokine network involved in the host immune response to periodontitis. International Journal of Oral Science, 2019, 11, 30.	3.6	326
412	Resolution of plaque-type psoriasis: what is left behind (and reinitiates the disease). Seminars in Immunopathology, 2019, 41, 633-644.	2.8	41
413	Psoriasis After Exposure to Angiotensin-Converting Enzyme Inhibitors: French Pharmacovigilance Data and Review of the Literature. Drug Safety, 2019, 42, 1507-1513.	1.4	11
414	A modern approach to the treatment of plaque psoriasis. Acta Pharmaceutica, 2019, 69, 511-523.	0.9	9
415	Neutrophils in Psoriasis. Frontiers in Immunology, 2019, 10, 2376.	2.2	148
416	Nanodermatologyâ€based solutions for psoriasis: Stateâ€ofâ€the art and future prospects. Dermatologic Therapy, 2019, 32, e13113.	0.8	24
417	C5a/C5aR1 Pathway Is Critical for the Pathogenesis of Psoriasis. Frontiers in Immunology, 2019, 10, 1866.	2.2	16
418	Next-Generation Sequencing Technologies for Early-Stage Cutaneous T-Cell Lymphoma. Frontiers in Medicine, 2019, 6, 181.	1.2	14
419	Silica-based nanosystems for therapeuticÂapplications in the skin. Nanomedicine, 2019, 14, 2243-2267.	1.7	17
420	The importance of the neuroâ€immunoâ€cutaneous system on human skin equivalent design. Cell Proliferation, 2019, 52, e12677.	2.4	44

#	Article	IF	Citations
421	Instantaneous depolarization of T cells via dopamine receptors, and inhibition of activated T cells of Psoriasis patients and inflamed human skin, by D1â€like receptor agonist: Fenoldopam. Immunology, 2019, 158, 171-193.	2.0	13
422	The Pathogenic Role of Dysregulated Epigenetic Modifications in Autoimmune Diseases. Frontiers in Immunology, 2019, 10, 2305.	2.2	46
423	Keratinocyte exosomes activate neutrophils and enhance skin inflammation in psoriasis. FASEB Journal, 2019, 33, 13241-13253.	0.2	74
424	Apremilast mechanism of efficacy in systemic-naive patients with moderate plaque psoriasis: Pharmacodynamic results from the UNVEIL study. Journal of Dermatological Science, 2019, 96, 126-133.	1.0	9
425	MiR-125b-5p and miR-181b-5p inhibit keratinocyte proliferation in skin by targeting Akt3. European Journal of Pharmacology, 2019, 862, 172659.	1.7	25
426	Retinoids as an Immunity-modulator in Dermatology Disorders. Archivum Immunologiae Et Therapiae Experimentalis, 2019, 67, 355-365.	1.0	11
427	Mesenchymal stem cells in psoriatic lesions affect the skin microenvironment through circular <scp>RNA</scp> . Experimental Dermatology, 2019, 28, 292-299.	1.4	26
428	Androgen deprivation therapy for prostate cancer and the risk of autoimmune diseases. Prostate Cancer and Prostatic Diseases, 2019, 22, 475-482.	2.0	28
429	Familial Aggregation of Psoriasis and Co-Aggregation of Autoimmune Diseases in Affected Families. Journal of Clinical Medicine, 2019, 8, 115.	1.0	18
430	Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab. Journal of Allergy and Clinical Immunology, 2019, 143, 2158-2169.	1.5	47
431	Ghrelin protects against contact dermatitis and psoriasiform skin inflammation by antagonizing TNF-α/NF-κB signaling pathways. Scientific Reports, 2019, 9, 1348.	1.6	36
432	Low TNFAIP3 expression in psoriatic skin promotes disease susceptibility and severity. PLoS ONE, 2019, 14, e0217352.	1.1	12
433	Current understanding of the role of dietary lipids in the pathophysiology of psoriasis. Journal of Dermatological Science, 2019, 94, 314-320.	1.0	20
434	Nanostructured supramolecular hydrogels: Towards the topical treatment of Psoriasis and other skin diseases. Colloids and Surfaces B: Biointerfaces, 2019, 181, 657-670.	2.5	24
435	Inhibition of NLRP3 inflammasome-mediated pyroptosis in macrophage by cycloastragenol contributes to amelioration of imiquimod-induced psoriasis-like skin inflammation in mice. International Immunopharmacology, 2019, 74, 105682.	1.7	57
436	MiR-21 binding site SNP within ITGAM associated with psoriasis susceptibility in women. PLoS ONE, 2019, 14, e0218323.	1.1	6
437	The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases. Pharmacological Reviews, 2019, 71, 345-382.	7.1	115
438	Caspase-11–Mediated Cell Death Contributes to the Pathogenesis of Imiquimod-Induced Psoriasis. Journal of Investigative Dermatology, 2019, 139, 2389-2393.e3.	0.3	8

#	Article	IF	CITATIONS
439	Adenoviral gene transfer of a singleâ€chain ILâ€23 induces psoriatic arthritis–like symptoms in NOD mice. FASEB Journal, 2019, 33, 9505-9515.	0.2	7
440	The contribution of IL-17 to the development of autoimmunity in psoriasis. Innate Immunity, 2019, 25, 337-343.	1.1	17
441	Differential Roles of the mTOR-STAT3 Signaling in Dermal $\hat{I}^3\hat{I}$ Cell Effector Function in Skin Inflammation. Cell Reports, 2019, 27, 3034-3048.e5.	2.9	46
442	Are new variants of psoriasis therapy (IL â€17 inhibitors) safe?. International Journal of Dermatology, 2019, 58, 1360-1365.	0.5	6
443	Hyperglycemia Is Associated with Psoriatic Inflammation in Both Humans and Mice. Journal of Investigative Dermatology, 2019, 139, 1329-1338.e7.	0.3	26
444	The role of GNLY gene polymorphisms in psoriasis pathogenesis. Anais Brasileiros De Dermatologia, 2019, 94, 198-203.	0.5	13
445	Synthesis and identification of quinoline derivatives as topoisomerase I inhibitors with potent antipsoriasis activity in an animal model. Bioorganic Chemistry, 2019, 88, 102899.	2.0	9
446	CD30L/CD30 protects against psoriasiform skin inflammation by suppressing Th17-related cytokine production by $\hat{V}^34+\hat{I}^3\hat{I}$ T cells. Journal of Autoimmunity, 2019, 101, 70-85.	3.0	8
447	Evaluating the Role of <scp>Janus Kinase</scp> Pathways in Platelet Homeostasis Using a Systems Modeling Approach. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 478-488.	1.3	12
448	Combining Understanding of Immunological Mechanisms and Genetic Variants Toward Development of Personalized Medicine for Psoriasis Patients. Frontiers in Genetics, 2019, 10, 395.	1.1	14
449	Association of <i>HLA-C*06:02 </i> Status With Differential Response to Ustekinumab in Patients With Psoriasis. JAMA Dermatology, 2019, 155, 708.	2.0	36
450	Dendritic Cells. , 2019, , 53-63.		0
451	Berberine downregulates CDC6 and inhibits proliferation via targeting JAK-STAT3 signaling in keratinocytes. Cell Death and Disease, 2019, 10, 274.	2.7	47
452	Revisiting the combinatorial potential of cytokine subunits in the IL-12 family. Biochemical Pharmacology, 2019, 165, 240-248.	2.0	24
453	Caspase 1/11 Deficiency or Pharmacological Inhibition Mitigates Psoriasis-Like Phenotype inÂMice. Journal of Investigative Dermatology, 2019, 139, 1306-1317.	0.3	16
454	Neutrophil exosomes enhance the skin autoinflammation in generalized pustular psoriasis <i>via</i> activating keratinocytes. FASEB Journal, 2019, 33, 6813-6828.	0.2	55
455	Integrated analysis of gene expression profiles identifies transcription factors potentially involved in psoriasis pathogenesis. Journal of Cellular Biochemistry, 2019, 120, 12582-12594.	1.2	11
456	Defective Induction of COX-2 Expression by Psoriatic Fibroblasts Promotes Pro-inflammatory Activation of Macrophages. Frontiers in Immunology, 2019, 10, 536.	2.2	22

#	Article	IF	Citations
457	R. nukuhivensis acts by reinforcing skin barrier function, boosting skin immunity and by inhibiting IL-22 induced keratinocyte hyperproliferation. Scientific Reports, 2019, 9, 4132.	1.6	4
458	Brodalumab for the treatment of plaque psoriasis: up-to-date. Expert Opinion on Biological Therapy, 2019, 19, 287-292.	1.4	27
459	Myeloid C-type lectin receptors in skin/mucoepithelial diseases and tumors. Journal of Leukocyte Biology, 2019, 106, 903-917.	1.5	19
460	Long noncoding RNA expression profile and functional analysis in psoriasis. Molecular Medicine Reports, 2019, 19, 3421-3430.	1.1	17
461	IL-17 and IL-22 Promote Keratinocyte Stemness in the Germinative Compartment in Psoriasis. Journal of Investigative Dermatology, 2019, 139, 1564-1573.e8.	0.3	48
462	T cell receptor signaling for $\hat{I}^3\hat{I}$ T cell development. Inflammation and Regeneration, 2019, 39, 6.	1.5	51
463	<i>Artemisia anomala</i> extracts enhance the viability and antioxidation capacity of human keratinocytes. Tropical Journal of Pharmaceutical Research, 2019, 18, 61.	0.2	4
464	Oleic acid as the active agent and lipid matrix in cilomilast-loaded nanocarriers to assist PDE4 inhibition of activated neutrophils for mitigating psoriasis-like lesions. Acta Biomaterialia, 2019, 90, 350-361.	4.1	20
465	Inflammasome Signaling and Impaired Vascular Health in Psoriasis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 787-798.	1.1	66
466	Dermal mesenchymal stem cells: a resource of migration-associated function in psoriasis?. Stem Cell Research and Therapy, 2019, 10, 54.	2.4	15
467	Classification of Genetically Defined Autoinflammatory Diseases. , 2019, , 167-201.		6
468	Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis. Journal of the American Academy of Dermatology, 2019, 80, 714-721.	0.6	70
469	Neutrophil Extracellular Traps Induce HumanÂTh17 Cells: Effect of Psoriasis-Associated TRAF3IP2 Genotype. Journal of Investigative Dermatology, 2019, 139, 1245-1253.	0.3	54
470	Augmenting a Psoriasis-patient Doctor-dialogue through Intergrating Real Face and Maps of Psoriasis Pathology. , 2019, , .		0
471	Candida Infections in Clinical Trials of Ixekizumab (Taltz), an Interleukin-17A Monoclonal Antibody, in Patients With Psoriasis or Psoriatic Arthritis. Journal of the Dermatology Nurses' Association, 2019, 11, 250-263.	0.1	4
472	Optimal Control Problems for a Mathematical Model of the Treatment of Psoriasis. Computational Mathematics and Modeling, 2019, 30, 352-363.	0.2	3
473	The role of epigenetics and immunological imbalance in the etiopathogenesis of psoriasis and psoriatic arthritis. Therapeutic Advances in Musculoskeletal Disease, 2019, 11, 1759720X1988650.	1.2	29
474	Risankizumab in moderate-to-severe plaque psoriasis. Immunotherapy, 2019, 11, 1357-1370.	1.0	5

#	ARTICLE	IF	CITATIONS
475	Effective treatment with balneophototherapy and narrowband UVB monotherapy reduces skin homing $Th17/Tc17$ and $Th22/Tc22$ effector cells in peripheral blood in patients with psoriasis. Journal of Dermatological Science, 2019, 96, 110-112.	1.0	2
476	IL-23 induces regulatory T cell plasticity with implications for inflammatory skin diseases. Scientific Reports, 2019, 9, 17675.	1.6	36
477	Etanercept reduces anxiety and depression in psoriasis patients, and sustained depression correlates with reduced therapeutic response to etanercept. Annales De Dermatologie Et De Venereologie, 2019, 146, 363-371.	0.5	16
478	Emerging Topical and Systemic JAK Inhibitors in Dermatology. Frontiers in Immunology, 2019, 10, 2847.	2.2	191
479	Application of an In Vitro Psoriatic Skin Model to Study Cutaneous Metabolization of Tazarotene. Processes, 2019, 7, 871.	1.3	10
480	The IL17F His161Arg polymorphism, a potential risk locus for psoriasis, increases serum levels of interleukin-17F in an Asian population. Scientific Reports, 2019, 9, 18921.	1.6	14
481	Mesenchymal Stem Cells Alleviate Moderate-to-Severe Psoriasis by Reducing the Production of Type I Interferon (IFN-I) by Plasmacytoid Dendritic Cells (pDCs). Stem Cells International, 2019, 2019, 1-13.	1.2	35
482	Group IID, IIE, IIF and III secreted phospholipase A2s. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2019, 1864, 803-818.	1.2	20
483	Pathophysiology and inhibition of IL-23 signaling in psoriatic arthritis: A molecular insight. Clinical Immunology, 2019, 206, 15-22.	1.4	28
484	Inhibition of spleen tyrosine kinase attenuates psoriasis-like inflammation in mice through blockade of dendritic cell-Th17 inflammation axis. Biomedicine and Pharmacotherapy, 2019, 111, 347-358.	2.5	35
485	Psoriasis: Keratinocytes or Immune Cells – Which Is the Trigger?. Dermatology, 2019, 235, 91-100.	0.9	151
486	Usage of Droplet Digital PCR (ddPCR) Assays for T Cell Quantification in Cancer. Methods in Molecular Biology, 2019, 1884, 1-14.	0.4	13
487	Psoriasis and cardiovascular disease: the elusive link. International Reviews of Immunology, 2019, 38, 33-54.	1.5	32
488	Ras homolog gene family H (RhoH) deficiency induces psoriasis-like chronic dermatitis by promoting TH17Âcell polarization. Journal of Allergy and Clinical Immunology, 2019, 143, 1878-1891.	1.5	14
489	Recent Advances on Microbiota Involvement in the Pathogenesis of Autoimmunity. International Journal of Molecular Sciences, 2019, 20, 283.	1.8	52
490	Improvements in epidermal function prevent relapse of psoriasis: a selfâ€controlled study. Clinical and Experimental Dermatology, 2019, 44, 654-657.	0.6	18
491	ILâ€23―and Imiquimod―Induced Models of Experimental Psoriasis in Mice. Current Protocols in Immunology, 2019, 125, e71.	3.6	29
492	IL28RA inhibits human epidermal keratinocyte proliferation by inhibiting cell cycle progression. Molecular Biology Reports, 2019, 46, 1189-1197.	1.0	8

#	Article	IF	CITATIONS
493	The Keratinocyte Transcriptome in Psoriasis: Pathways Related to Immune Responses, Cell Cycle and Keratinization. Acta Dermato-Venereologica, 2019, 99, 196-205.	0.6	52
494	Role of myeloid regulatory cells (MRCs) in maintaining tissue homeostasis and promoting tolerance in autoimmunity, inflammatory disease and transplantation. Cancer Immunology, Immunotherapy, 2019, 68, 661-672.	2.0	47
495	A Critical Role of the IL- $1\hat{l}^2\hat{a}$ "IL- $1R$ Signaling Pathway in Skin Inflammation and Psoriasis Pathogenesis. Journal of Investigative Dermatology, 2019, 139, 146-156.	0.3	152
496	Glucose metabolism in patients with psoriasis. British Journal of Dermatology, 2019, 180, 264-271.	1.4	17
497	Keratinocyte Expression of A20/TNFAIP3 Controls Skin Inflammation Associated with Atopic Dermatitis and Psoriasis. Journal of Investigative Dermatology, 2019, 139, 135-145.	0.3	42
498	Serum YKL-40 in patients with psoriasis vulgaris treated by narrow-band UVB phototherapy. Journal of Dermatological Treatment, 2019, 30, 545-548.	1.1	6
499	Ixekizumab provides superior efficacy compared with ustekinumab over 52Âweeks of treatment: Results from IXORA-S, a phase 3 study. Journal of the American Academy of Dermatology, 2019, 80, 70-79.e3.	0.6	77
500	Associations between PTPN2 gene polymorphisms and psoriasis in Northeastern China. Gene, 2019, 681, 73-79.	1.0	6
501	Genomic alterations driving psoriasis pathogenesis. Gene, 2019, 683, 61-71.	1.0	50
502	Blockade of TNF receptor superfamily 1 (TNFR1)–dependent and TNFR1-independent cell death is crucial for normal epidermal differentiation. Journal of Allergy and Clinical Immunology, 2019, 143, 213-228.e10.	1.5	11
503	Hyaluronan in the lymphatics: The key role of the hyaluronan receptor LYVE-1 in leucocyte trafficking. Matrix Biology, 2019, 78-79, 219-235.	1.5	90
504	Genetic variants and pathways implicated in a pediatric inflammatory bowel disease cohort. Genes and Immunity, 2019, 20, 131-142.	2.2	22
505	The role of the histamine H ₄ receptor in atopic dermatitis and psoriasis. British Journal of Pharmacology, 2020, 177, 490-502.	2.7	51
506	Management of psoriasis as a systemic disease: what is the evidence?. British Journal of Dermatology, 2020, 182, 840-848.	1.4	231
507	Kan-Lu-Hsiao-Tu-Tan, a traditional Chinese medicine formula, inhibits human neutrophil activation and ameliorates imiquimod-induced psoriasis-like skin inflammation. Journal of Ethnopharmacology, 2020, 246, 112246.	2.0	32
508	Evaluation of Galectin3 levels in psoriatic patients treated by narrow-band UVB phototherapy. Journal of Dermatological Treatment, 2020, 31, 758-762.	1.1	2
509	Different risk profiles of biologic agents for new-onset psoriasis in patients with rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 2020, 50, 36-41.	1.6	6
510	In vitro evaluation of Naltrexone HCl 1% Topical Cream in XemaTopâ,,¢ for psoriasis. Archives of Dermatological Research, 2020, 312, 145-154.	1.1	3

#	Article	IF	CITATIONS
511	Lysosomotropic beta blockers induce oxidative stress and IL23A production in Langerhans cells. Autophagy, 2020, 16, 1380-1395.	4.3	25
512	Anti-oxidative effects of superoxide dismutase 3 on inflammatory diseases. Journal of Molecular Medicine, 2020, 98, 59-69.	1.7	72
513	Dihydrochalcone Derivatives from Populus balsamifera L. Buds for the Treatment of Psoriasis. International Journal of Molecular Sciences, 2020, 21, 256.	1.8	22
514	Neuronal Regulation of Cutaneous Immunity. Journal of Immunology, 2020, 204, 264-270.	0.4	26
515	Recent Advances on the Anti-Inflammatory and Antioxidant Properties of Red Grape Polyphenols: In Vitro and In Vivo Studies. Antioxidants, 2020, 9, 35.	2.2	67
516	The role of IL-37 in skin and connective tissue diseases. Biomedicine and Pharmacotherapy, 2020, 122, 109705.	2.5	38
517	Epidermal autonomous VEGFA/Flt1/Nrp1 functions mediate psoriasis-like disease. Science Advances, 2020, 6, eaax5849.	4.7	37
518	Evaluation of monocyte to high-density lipoprotein ratio, lymphocytes, monocytes, and platelets in psoriasis. Anais Brasileiros De Dermatologia, 2020, 95, 40-45.	0.5	19
519	Granuloma annulare skin profile shows activation of T-helper cell type 1, T-helper cell type 2, and Janus kinase pathways. Journal of the American Academy of Dermatology, 2020, 83, 63-70.	0.6	42
520	BMP7 aberrantly induced in the psoriatic epidermis instructs inflammation-associated Langerhans cells. Journal of Allergy and Clinical Immunology, 2020, 145, 1194-1207.e11.	1.5	12
521	Tussilagonone Ameliorates Psoriatic Features inÂKeratinocytes and Imiquimod-Induced Psoriasis-Like Lesions in Mice via NRF2 Activation. Journal of Investigative Dermatology, 2020, 140, 1223-1232.e4.	0.3	25
522	Psoriatic epidermis expresses high level of inflammatory mediators and the CDK2/4 cyclinâ€dependent kinases are involved in the regulation of cellâ€cycle progression in epidermal cells. British Journal of Dermatology, 2020, 182, 533-534.	1.4	2
523	Dendritic cells: The driver of psoriasis. Journal of Dermatology, 2020, 47, 104-113.	0.6	77
524	Integrated microRNA/mRNA expression profiling of the skin of psoriasis patients. Journal of Dermatological Science, 2020, 97, 9-20.	1.0	24
525	CD200-CD200R1 signalling attenuates imiquimod-induced psoriatic inflammation by inhibiting the activation of skin inflammatory macrophages. International Immunopharmacology, 2020, 78, 106046.	1.7	4
526	Murine models of psoriasis and its applications in drug development. Journal of Pharmacological and Toxicological Methods, 2020, 101, 106657.	0.3	12
527	High Levels of Platelet-Lymphocyte Complexes in Patients with Psoriasis Are Associated with a Better Response to Anti–TNF-α Therapy. Journal of Investigative Dermatology, 2020, 140, 1176-1183.	0.3	10
528	Shedding light on the role of keratinocyte-derived extracellular vesicles on skin-homing cells. Stem Cell Research and Therapy, 2020, 11, 421.	2.4	15

#	Article	IF	CITATIONS
529	Transcriptome Profiling Analyses in Psoriasis: A Dynamic Contribution of Keratinocytes to the Pathogenesis. Genes, 2020, 11, 1155.	1.0	27
530	Dimethyl Fumarate and Its Esters: A Drug with Broad Clinical Utility?. Pharmaceuticals, 2020, 13, 306.	1.7	52
531	Oxymatrine ameliorates imiquimod-induced psoriasis pruritus and inflammation through inhibiting heat shock protein 90 and heat shock protein 60 expression in keratinocytes. Toxicology and Applied Pharmacology, 2020, 405, 115209.	1.3	19
532	Engineered Th17 Cell Differentiation Using a Photoactivatable Immune Modulator. Journal of the American Chemical Society, 2020, 142, 18103-18108.	6.6	5
533	A peptide derived from phage-display limits psoriasis-like lesions in mice. Heliyon, 2020, 6, e04162.	1.4	4
534	Second-Strand Synthesis-Based Massively Parallel scRNA-Seq Reveals Cellular States and Molecular Features of Human Inflammatory Skin Pathologies. Immunity, 2020, 53, 878-894.e7.	6.6	169
535	Genomeâ€wide association analysis of psoriasis patients treated with antiâ€₹NF drugs. Experimental Dermatology, 2020, 29, 1225-1232.	1.4	11
536	Inhibition of interleukin-2-inducible T-cell kinase causes reduction in imiquimod-induced psoriasiform inflammation through reduction of Th17 cells and enhancement of Treg cells in mice. Biochimie, 2020, 179, 146-156.	1.3	32
537	EZH2-dependent epigenetic modulation of histone H3 lysine-27 contributes to psoriasis by promoting keratinocyte proliferation. Cell Death and Disease, 2020, 11, 826.	2.7	27
538	Targeting Myeloid-Derived Suppressor Cells Is a Novel Strategy for Anti-Psoriasis Therapy. Mediators of Inflammation, 2020, 2020, 1-12.	1.4	13
539	Pharmacokinetics, pharmacodynamics and safety of the inverse retinoic acidâ€related orphan receptor γ agonist AZD0284. British Journal of Clinical Pharmacology, 2020, 86, 1398-1405.	1.1	10
540	Generalized hypertrichosis associated with the use of interleukin 17 blockers in 2 patients with psoriasis. JAAD Case Reports, 2020, 6, 683-685.	0.4	4
541	Hispidulin alleviates imiquimod-induced psoriasis-like skin inflammation by inhibiting splenic Th1/Th17 cell population and keratinocyte activation. International Immunopharmacology, 2020, 87, 106767.	1.7	11
542	Bilirubin nanomedicine alleviates psoriatic skin inflammation by reducing oxidative stress and suppressing pathogenic signaling. Journal of Controlled Release, 2020, 325, 359-369.	4.8	44
543	TLR2 Deficiency Exacerbates Imiquimod-Induced Psoriasis-Like Skin Inflammation through Decrease in Regulatory T Cells and Impaired IL-10 Production. International Journal of Molecular Sciences, 2020, 21, 8560.	1.8	11
544	A Novel Selective Sphingosine Kinase 2 Inhibitor, HWG-35D, Ameliorates the Severity of Imiquimod-Induced Psoriasis Model by Blocking Th17 Differentiation of NaÃve CD4 T Lymphocytes. International Journal of Molecular Sciences, 2020, 21, 8371.	1.8	12
545	Treatment of psoriasis with NFKBIZ siRNA using topical ionic liquid formulations. Science Advances, 2020, 6, eabb6049.	4.7	52
546	Lysophosphatidic Acid Receptor 5 Contributes to Imiquimod-Induced Psoriasis-Like Lesions through NLRP3 Inflammasome Activation in Macrophages. Cells, 2020, 9, 1753.	1.8	25

#	Article	IF	CITATIONS
547	Mixed profile of cytokines in paradoxical eczematous eruptions associated with anti-IL-17 therapy. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3619-3621.e1.	2.0	7
548	Immunoregulatory complement receptor-1 and leukocyte-associated Ig-like receptor-1 expression on leukocytes in <i>Psoriasis vulgaris</i> . Innate Immunity, 2020, 26, 683-692.	1.1	4
549	Regulating the Polarization of Macrophages: A Promising Approach to Vascular Dermatosis. Journal of Immunology Research, 2020, 2020, 1-13.	0.9	21
550	The TNF/ILâ€23/ILâ€17 axis—Headâ€toâ€head trials comparing different biologics in psoriasis treatment. Scandinavian Journal of Immunology, 2020, 92, e12946.	1.3	58
551	Updating and identifying three novel variants of the CARD14 gene in Chinese Han patients with psoriasis. Journal of Genetics, 2020, 99, 1.	0.4	2
552	Role of keratinocytes and immune cells in the anti-inflammatory effects of Tripterygium wilfordii Hook. f. in a murine model of psoriasis. Phytomedicine, 2020, 77, 153299.	2.3	32
553	The role of xenobiotics in triggering psoriasis. Archives of Toxicology, 2020, 94, 3959-3982.	1.9	8
554	Impact of AvÃ"ne Thermal Spring Water on immune cells. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 21-26.	1.3	13
555	Thymol activates TRPM8-mediated Ca2+ influx for its antipruritic effects and alleviates inflammatory response in Imiquimod-induced mice. Toxicology and Applied Pharmacology, 2020, 407, 115247.	1.3	18
556	Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial. Journal of Dermatological Treatment, 2020, , 1-7.	1.1	13
557	Psoriasis and Antimicrobial Peptides. International Journal of Molecular Sciences, 2020, 21, 6791.	1.8	63
558	The role of Th17 cells in psoriasis. Immunologic Research, 2020, 68, 296-309.	1.3	63
559	Efficacy and safety of fire needle therapy for blood stasis syndrome of plaque psoriasis: protocol for a randomized, single-blind, multicenter clinical trial. Trials, 2020, 21, 739.	0.7	5
560	C5a/C5aR1 mediates IMQâ€induced psoriasiform skin inflammation by promoting ILâ€17A production from γδâ cells. FASEB Journal, 2020, 34, 10590-10604.	€ 7 0.2	9
561	Single-cell RNA-Seq reveals the transcriptional landscape and heterogeneity of skin macrophages in Vsir ^{-/-} murine psoriasis. Theranostics, 2020, 10, 10483-10497.	4.6	32
562	The role of Langerhans cells in epidermal homeostasis and pathogenesis of psoriasis. Journal of Cellular and Molecular Medicine, 2020, 24, 11646-11655.	1.6	22
563	Long-Term and Clinically Relevant Full-Thickness Human Skin Equivalent for Psoriasis. ACS Applied Bio Materials, 2020, 3, 6639-6647.	2.3	9
564	Evaluation of a Product Containing Xyloglucan and Pea Protein on Skin Barrier Permeability. Skin Pharmacology and Physiology, 2020, 33, 231-236.	1.1	8

#	Article	IF	Citations
565	Imiquimod does not elicit inflammatory responses in the skin of the naked mole rat (Heterocephalus) Tj ETQq0 0	0 rgBT /Ov	reglock 10 Tf
566	Microalgae as Potential Anti-Inflammatory Natural Product Against Human Inflammatory Skin Diseases. Frontiers in Pharmacology, 2020, 11, 1086.	1.6	33
567	Quantitative analysis of differentially expressed proteins in psoriasis vulgaris using tandem mass tags and parallel reaction monitoring. Clinical Proteomics, 2020, 17, 30.	1.1	9
568	MicroRNAs in Several Cutaneous Autoimmune Diseases: Psoriasis, Cutaneous Lupus Erythematosus and Atopic Dermatitis. Cells, 2020, 9, 2656.	1.8	24
569	Small interfering RNA targeting of keratin 17 reduces inflammation in imiquimod-induced psoriasis-like dermatitis. Chinese Medical Journal, 2020, 133, 2910-2918.	0.9	8
570	Enhanced IL-36R signaling promotes barrier impairment and inflammation in skin and intestine. Science Immunology, 2020, 5, .	5.6	21
571	Pharmacogenetics Update on Biologic Therapy in Psoriasis. Medicina (Lithuania), 2020, 56, 719.	0.8	11
572	Human skin explant model for the investigation of topical therapeutics. Scientific Reports, 2020, 10, 21192.	1.6	32
573	Association between mutation of interleukin 36 receptor antagonist and generalized pustular psoriasis. Medicine (United States), 2020, 99, e23068.	0.4	18
574	Association Between Psoriasis and Dementia: Current Evidence. Frontiers in Aging Neuroscience, 2020, 12, 570992.	1.7	20
575	Therapeutic Potential of Heat Shock Proteins in Human Inflammation/Autoimmune Skin Diseases: Future Directions. Heat Shock Proteins, 2020, , 325.	0.2	1
576	<scp>MALT</scp> 1 targeting suppresses <scp>CARD</scp> 14â€induced psoriatic dermatitis in mice. EMBO Reports, 2020, 21, e49237.	2.0	18
577	Oncostatin M upregulates Livin to promote keratinocyte proliferation and survival via ERK and STAT3 signalling pathways. Experimental Physiology, 2020, 105, 1151-1158.	0.9	10
578	Management of Paediatric Psoriasis by Paediatricians: A Questionnaire-Based Survey. Dermatology and Therapy, 2020, 10, 671-680.	1.4	4
579	Skin expression of IL-23 drives the development of psoriasis and psoriatic arthritis in mice. Scientific Reports, 2020, 10, 8259.	1.6	30
580	Mesenchymal stem cells for the treatment of psoriasis: a comprehensive review. Clinical and Experimental Dermatology, 2020, 45, 824-830.	0.6	18
581	Systemic immunobiological, immunosuppressant, and oncologic agents for the treatment of dermatologic diseases during the SARSâ€CoVâ€2 (COVIDâ€19) pandemic emergency: A quick review for a quick consultation. Dermatologic Therapy, 2020, 33, e13537.	0.8	4
582	Circulating CD14+HLA-DRâ [^] /low Myeloid-Derived Suppressor Cells as Potential Biomarkers for the Identification of Psoriasis TCM Blood-Heat Syndrome and Blood-Stasis Syndrome. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-11.	0.5	4

#	Article	IF	CITATIONS
583	The Role of Gut Microbiome in Psoriasis: Oral Administration of Staphylococcus aureus and Streptococcus danieliae Exacerbates Skin Inflammation of Imiquimod-Induced Psoriasis-Like Dermatitis. International Journal of Molecular Sciences, 2020, 21, 3303.	1.8	31
584	Identification of <i>N</i> -Phenyl-7 <i>H</i> -pyrrolo[2,3- <i>d</i>]pyrimidin-4-amine Derivatives as Novel, Potent, and Selective NF-κB Inducing Kinase (NIK) Inhibitors for the Treatment of Psoriasis. Journal of Medicinal Chemistry, 2020, 63, 6748-6773.	2.9	16
585	Transdermal and bioactive nanocarriers. , 2020, , 17-33.		1
586	Immune Modulation of Monocytes Dampens the IL-17+ $\hat{I}^3\hat{I}$ T Cell Response and Associated Psoriasis Pathology in Mice. Journal of Investigative Dermatology, 2020, 140, 2398-2407.e1.	0.3	5
587	Notch-Hes1 Signaling Regulates IL-17A $<$ sup $>+sup><i>^{13}1^{<}2/i><sup>+sup$	1.4	7
588	Pivotal role of CD103 in the development of psoriasiform dermatitis. Scientific Reports, 2020, 10, 8371.	1.6	3
589	Complement component 3 prevents imiquimod-induced psoriatic skin inflammation by inhibiting apoptosis in mice. International Immunopharmacology, 2020, 85, 106692.	1.7	8
590	Psoriatic arthritis under the influence of IFNÎ ³ . Clinical Immunology, 2020, 218, 108513.	1.4	10
591	Pathogenesis of psoriasis in the "omic―era. Part I. Epidemiology, clinical manifestation, immunological and neuroendocrine disturbances. Postepy Dermatologii I Alergologii, 2020, 37, 135-153.	0.4	28
592	Successful Regulatory T Cell-Based Therapy Relies on Inhibition of T Cell Effector Function and Enrichment of FOXP3+ Cells in a Humanized Mouse Model of Skin Inflammation. Journal of Immunology Research, 2020, 2020, 1-11.	0.9	0
593	Skin Mycobiome of Psoriasis Patients is Retained during Treatment with TNF and IL-17 Inhibitors. International Journal of Molecular Sciences, 2020, 21, 3892.	1.8	9
594	Therapeutic anti-psoriatic effects of myeloid-derived suppressor cells in combination with systemic tacrolimus (FK-506) in an imiquimod-induced mouse model of psoriasis. International Immunopharmacology, 2020, 86, 106553.	1.7	2
595	Targeted Treatment for Erythrodermic Psoriasis: Rationale and Recent Advances. Drugs, 2020, 80, 525-534.	4.9	20
596	Plexin-B2 in psoriasis; a clinical and immunohistochemical study. Journal of Immunoassay and Immunochemistry, 2020, 41, 718-728.	0.5	7
597	Innate Lymphocytes in Psoriasis. Frontiers in Immunology, 2020, 11, 242.	2.2	33
598	Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities. Frontiers in Pharmacology, 2020, 11, 117.	1.6	80
599	Unbalanced Sphingolipid Metabolism and Its Implications for the Pathogenesis of Psoriasis. Molecules, 2020, 25, 1130.	1.7	15
600	The pathogenic role of innate lymphoid cells in autoimmune-related and inflammatory skin diseases. Cellular and Molecular Immunology, 2020, 17, 335-346.	4.8	23

#	Article	IF	CITATIONS
601	Small molecules under development for psoriasis: on the road to the individualized therapies. Archives of Dermatological Research, 2020, 312, 611-627.	1.1	11
602	Activated Platelets Induce Endothelial Cell Inflammatory Response in Psoriasis via COX-1. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1340-1351.	1.1	56
603	Treating Psoriasis With Halobetasol Propionate and Tazarotene Combination: A Review of Phase II and III Clinical Trials. Annals of Pharmacotherapy, 2020, 54, 872-878.	0.9	4
604	Diterpenoids and Triterpenoids From Frankincense Are Excellent Anti-psoriatic Agents: An in silico Approach. Frontiers in Chemistry, 2020, 8, 486.	1.8	12
605	Telemedicine approach for psoriasis management, time for application? A systematic review of published studies. Dermatologic Therapy, 2020, 33, e13908.	0.8	14
606	Chronic Alcohol Consumption Exacerbates the Severity of Psoriasiform Dermatitis in Mice. Alcoholism: Clinical and Experimental Research, 2020, 44, 1728-1733.	1.4	4
607	A transcriptome-based approach to identify functional modules within and across primary human immune cells. PLoS ONE, 2020, 15, e0233543.	1.1	10
608	Immunohistochemical expression of BCAP 31 in chronic plaque psoriasis. Journal of Immunoassay and Immunochemistry, 2020, 41, 852-863.	0.5	2
609	Atezolizumab-induced psoriasis in a patient with metastatic lung cancerâ€"a case report. Translational Cancer Research, 2020, 9, 3776-3782.	0.4	4
610	IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications. Frontiers in Immunology, 2019, 10, 3096.	2.2	122
611	Lipidomic Analysis Reveals Specific Differences between Fibroblast and Keratinocyte Ceramide Profile of Patients with Psoriasis Vulgaris. Molecules, 2020, 25, 630.	1.7	32
612	Bacterial Autoimmune Drug Metabolism Transforms an Immunomodulator into Structurally and Functionally Divergent Antibiotics. Angewandte Chemie, 2020, 132, 7945-7954.	1.6	3
613	Bacterial Autoimmune Drug Metabolism Transforms an Immunomodulator into Structurally and Functionally Divergent Antibiotics. Angewandte Chemie - International Edition, 2020, 59, 7871-7880.	7.2	12
614	Psoriasis-Like Inflammation Induced Renal Dysfunction through the TLR/NF- $\langle i \rangle \hat{I}^2 \langle i \rangle$ B Signal Pathway. BioMed Research International, 2020, 2020, 1-11.	0.9	17
615	Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. Journal of the American Academy of Dermatology, 2020, 82, 1445-1486.	0.6	184
616	Enhancing reproducibility of gene expression analysis with known protein functional relationships: The concept of well-associated protein. PLoS Computational Biology, 2020, 16, e1007684.	1.5	2
617	Nanocarriers for topical delivery in psoriasis. , 2020, , 75-96.		21
618	Keratinocytes Derived from Patient-Specific Induced Pluripotent Stem Cells Recapitulate the Genetic Signature of Psoriasis Disease. Stem Cells and Development, 2020, 29, 383-400.	1.1	29

#	Article	IF	CITATIONS
619	Spermidine Suppresses Inflammatory DC Function by Activating the FOXO3 Pathway and Counteracts Autoimmunity. IScience, 2020, 23, 100807.	1.9	49
620	Negative regulation of dendritic cell activation in psoriasis mediated via CD100–plexinâ€B2. Journal of Pathology, 2020, 250, 409-419.	2.1	10
621	Role of neuroimmune circuits and pruritus in psoriasis. Experimental Dermatology, 2020, 29, 414-426.	1.4	39
622	Psoriasis and Psoriatic Arthritis Cardiovascular Disease Endotypes Identified by Red Blood Cell Distribution Width and Mean Platelet Volume. Journal of Clinical Medicine, 2020, 9, 186.	1.0	50
623	JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors. Drugs, 2020, 80, 341-352.	4.9	101
624	Metformin ameliorates animal models of dermatitis. Inflammopharmacology, 2020, 28, 1293-1300.	1.9	2
625	Efficacy and Safety of Jueyin Granules for Patients with Mild-to-Moderate Psoriasis Vulgaris: Protocol for a Multicenter Randomized Placebo-Controlled Trial. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-9.	0.5	2
626	Therapeutic Effects of Anti–Bone Morphogenetic Protein and Activin Membraneâ€Bound Inhibitor Treatment in Psoriasis and Arthritis. Arthritis and Rheumatology, 2020, 72, 1547-1558.	2.9	3
627	Patients with psoriatic arthritis have higher levels of FeNO than those with only psoriasis, which may reflect a higher prevalence of a subclinical respiratory involvement. Clinical Rheumatology, 2020, 39, 2981-2988.	1.0	20
628	Therapeutic treatment with Ibrutinib attenuates imiquimod-induced psoriasis-like inflammation in mice through downregulation of oxidative and inflammatory mediators in neutrophils and dendritic cells. European Journal of Pharmacology, 2020, 877, 173088.	1.7	47
629	Glycoconjugation as a Promising Treatment Strategy for Psoriasis. Journal of Pharmacology and Experimental Therapeutics, 2020, 373, 204-212.	1.3	7
630	Endoplasmic reticulum stress links psoriasis vulgaris with keratinocyte inflammation. Postepy Dermatologii I Alergologii, 2020, 37, 34-40.	0.4	7
631	<p>Cyclodextrin-Modified CeO₂ Nanoparticles as a Multifunctional Nanozyme for Combinational Therapy of Psoriasis</p> . International Journal of Nanomedicine, 2020, Volume 15, 2515-2527.	3.3	30
632	ER Stress Regulates Immunosuppressive Function of Myeloid Derived Suppressor Cells in Leprosy that Can Be Overcome in the Presence of IFN- \hat{l}^3 . IScience, 2020, 23, 101050.	1.9	6
633	Differential Requirement for CCR6 in IL-23–Mediated Skin and Joint Inflammation. Journal of Investigative Dermatology, 2020, 140, 2386-2397.	0.3	8
634	Repression of miR-142–3p alleviates psoriasis-like inflammation by repressing proliferation and promoting apoptosis of keratinocytes via targeting Sema3A. Molecular and Cellular Probes, 2020, 52, 101573.	0.9	13
635	Brodalumab: A new way to inhibit IL â€17 in psoriasis. Dermatologic Therapy, 2020, 33, e13403.	0.8	20
636	<p>Dimethyl Fumarate Targets MSK1, RSK1, 2 and IKKÎ \pm /β Kinases and Regulates NF-κB /p65 Activation in Psoriasis: A Demonstration of the Effect on Peripheral Blood Mononuclear Cells, Drawn from Two Patients with Severe Psoriasis Before and After Treatment with Dimethyl Fumarate</p>. Psoriasis: Targets and Therapy. 2020. Volume 10. 1-11.	1.2	5

#	Article	IF	Citations
637	Expression and functional regulation of gap junction protein connexin 43 in dermal mesenchymal stem cells from psoriasis patients. Acta Histochemica, 2020, 122, 151550.	0.9	4
638	DC591017, a phosphodiesterase-4 (PDE4) inhibitor with robust anti-inflammation through regulating PKA-CREB signaling. Biochemical Pharmacology, 2020, 177, 113958.	2.0	19
639	Cancer risk in patients with psoriasis: should we be paying more attention?. Expert Review of Clinical Immunology, 2020, 16, 479-492.	1.3	24
640	The JNK Signaling Pathway in Inflammatory Skin Disorders and Cancer. Cells, 2020, 9, 857.	1.8	141
641	Animal models of psoriasis—highlights and drawbacks. Journal of Allergy and Clinical Immunology, 2021, 147, 439-455.	1.5	51
642	Interleukinâ€9 serves as a key link between systemic inflammation and angiogenesis in psoriasis. Clinical and Experimental Dermatology, 2021, 46, 50-57.	0.6	14
643	Autophagy-based unconventional secretion of HMGB1 by keratinocytes plays a pivotal role in psoriatic skin ini¬,ammation. Autophagy, 2021, 17, 529-552.	4.3	81
644	DGT, a novel heterocyclic diterpenoid, effectively suppresses psoriasis via inhibition of STAT3 phosphorylation. British Journal of Pharmacology, 2021, 178, 636-653.	2.7	9
645	Interferon-stimulated GTPases in autoimmune and inflammatory diseases: promising role for the guanylate-binding protein (GBP) family. Rheumatology, 2021, 60, 494-506.	0.9	17
646	Small Extracellular Vesicles Containing miR-381-3p from Keratinocytes Promote TÂHelper Type 1 and T Helper Type 17 Polarization in Psoriasis. Journal of Investigative Dermatology, 2021, 141, 563-574.	0.3	27
647	Granzyme B Inhibition by Tofacitinib Blocks the Pathology Induced by CD8 T Cells in Cutaneous Leishmaniasis. Journal of Investigative Dermatology, 2021, 141, 575-585.	0.3	24
648	Fire Needle Therapy for the Treatment of Psoriasis: A Quantitative Evidence Synthesis. Journal of Alternative and Complementary Medicine, 2021, 27, 24-37.	2.1	14
649	Protective Effects of Anti-depressants against the Subsequent Development of Psoriasis in Patients with Major Depressive Disorder: a Cohort Study. Journal of Affective Disorders, 2021, 281, 590-596.	2.0	8
650	Metabolomic profiling reveals amino acid and carnitine alterations as metabolic signatures in psoriasis. Theranostics, 2021, 11, 754-767.	4.6	48
651	ZnO NPs delay the recovery of psoriasis-like skin lesions through promoting nuclear translocation of p-NFκB p65 and cysteine deficiency in keratinocytes. Journal of Hazardous Materials, 2021, 410, 124566.	6.5	23
652	OVOL1 Regulates Psoriasis-Like Skin Inflammation and Epidermal Hyperplasia. Journal of Investigative Dermatology, 2021, 141, 1542-1552.	0.3	13
653	The inflammation in cutaneous lichen planus is dominated by IFNâ€i and ILâ€21â€"A basis for therapeutic JAK1 inhibition. Experimental Dermatology, 2021, 30, 262-270.	1.4	35
654	Depletion of LAGâ€3 ⁺ T Cells Translated to Pharmacology and Improvement in Psoriasis Disease Activity: A Phase I Randomized Study of mAb GSK2831781. Clinical Pharmacology and Therapeutics, 2021, 109, 1293-1303.	2.3	18

#	Article	IF	CITATIONS
655	Association of COVIDâ€19 with skin diseases and relevant biologics: a crossâ€sectional study using nationwide claim data in South Korea*. British Journal of Dermatology, 2021, 184, 296-303.	1.4	14
656	Enhanced Inflammasome Activity in Patients with Psoriasis Promotes Systemic Inflammation. Journal of Investigative Dermatology, 2021, 141, 586-595.e5.	0.3	51
657	The emerging roles of circular RNAs in regulating the fate of stem cells. Molecular and Cellular Biochemistry, 2021, 476, 231-246.	1.4	5
658	An Autocrine Circuit of IL-33 in Keratinocytes Is Involved in the Progression of Psoriasis. Journal of Investigative Dermatology, 2021, 141, 596-606.e7.	0.3	33
659	The cytokine ILâ€17A as a marker of treatment resistance in major depressive disorder?. European Journal of Neuroscience, 2021, 53, 172-182.	1.2	24
660	FOXM1 regulates the proliferation, apoptosis and inflammatory response of keratinocytes through the NF-κB signaling pathway. Human and Experimental Toxicology, 2021, 40, 1130-1140.	1.1	11
661	The Role of Leptin in the Association between Obesity and Psoriasis. Biomolecules and Therapeutics, 2021, 29, 11-21.	1.1	26
662	Zdhhc2 Is Essential for Plasmacytoid Dendritic Cells Mediated Inflammatory Response in Psoriasis. Frontiers in Immunology, 2020, 11, 607442.	2.2	12
663	Pruritus in psoriasis and atopic dermatitis: current treatments and new perspectives. Pharmacological Reports, 2021, 73, 443-453.	1.5	20
664	Repurposing approved therapeutics for new indication: Addressing unmet needs in psoriasis treatment. Current Research in Pharmacology and Drug Discovery, 2021, 2, 100041.	1.7	12
665	Obesity and Skin Problems. , 2021, , 25-48.		0
666	The association of HLA-C and ERAP1 polymorphisms in early and late onset psoriasis and psoriatic arthritis patients of Hungary. Postepy Dermatologii I Alergologii, 2021, 38, 43-51.	0.4	3
667	Interleukin-17 family members in health and disease. International Immunology, 2021, 33, 723-729.	1.8	41
668	Lysophosphatidic acid mediates the pathogenesis of psoriasis by activating keratinocytes through LPAR5. Signal Transduction and Targeted Therapy, 2021, 6, 19.	7.1	9
669	Calcium channel blocker exposure and psoriasis risk: Pharmacovigilance investigation and literature data. Therapie, 2021, 76, 5-11.	0.6	7
670	Role of subnetworks mediated by \$\$hbox {TNF}alpha\$\$, IL-23/IL-17 and IL-15 in a network involved in the pathogenesis of psoriasis. Scientific Reports, 2021, 11, 2204.	1.6	6
671	Dendrimers formulations to enhance skin drug delivery., 2021,, 399-416.		2
672	Monovalent antibody-conjugated lipid-polymer nanohybrids for active targeting to desmoglein 3 of keratinocytes to attenuate psoriasiform inflammation. Theranostics, 2021, 11, 4567-4584.	4.6	7

#	Article	IF	Citations
673	Cytokines in psoriasis. Advances in Clinical Chemistry, 2021, 100, 171-204.	1.8	45
674	Clinical Significance of Helicobacter pylori Infection on Psoriasis Severity. Journal of Interferon and Cytokine Research, 2021, 41, 44-51.	0.5	2
675	DZ2002 alleviates psoriasis-like skin lesions via differentially regulating methylation of GATA3 and LCN2 promoters. International Immunopharmacology, 2021, 91, 107334.	1.7	6
676	Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview. Frontiers in Immunology, 2021, 12, 637829.	2.2	140
678	Immune repertoire: Revealing the "real-time―adaptive immune response in autoimmune diseases. Autoimmunity, 2021, 54, 61-75.	1.2	3
679	Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet, The, 2021, 397, 754-766.	6.3	222
680	Evaluation of antipsoriatic activity of gel containing Pongamia pinnata extract on Imiquimod-induced psoriasis. Clinical Phytoscience, 2021, 7, .	0.8	4
681	Inhibition of phospholipases suppresses progression of psoriasis through modulation of inflammation. Experimental Biology and Medicine, 2021, 246, 1253-1262.	1.1	7
682	Phosphodiesterase-4 Inhibition in Psoriasis. Psoriasis: Targets and Therapy, 2021, Volume 11, 21-29.	1.2	21
683	Liangxue Jiedu Formula Improves Psoriasis and Dyslipidemia Comorbidity via PI3K/Akt/mTOR Pathway. Frontiers in Pharmacology, 2021, 12, 591608.	1.6	10
684	Acitretin Promotes the Differentiation of Myeloid-Derived Suppressor Cells in the Treatment of Psoriasis. Frontiers in Medicine, 2021, 8, 625130.	1.2	5
685	m6A RNA Methylation in Systemic Autoimmune Diseases—A New Target for Epigenetic-Based Therapy?. Pharmaceuticals, 2021, 14, 218.	1.7	16
686	Emerging Therapeutics for Immune Tolerance: Tolerogenic Vaccines, T cell Therapy, and IL-2 Therapy. Frontiers in Immunology, 2021, 12, 657768.	2.2	52
687	Evaluation of expression of Toll-Like Receptors 7 and 9, proliferation, and cytoskeletal biomarkers in plaque and guttate psoriasis: A pilot morphological study. European Journal of Histochemistry, 2021, 65, .	0.6	3
688	Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies. Journal of Allergy and Clinical Immunology, 2021, 147, 857-869.e7.	1.5	45
689	Role of the long non‑coding RNA HOTAIR/miR‑126 axis in an in vitro psoriasis model. Experimental and Therapeutic Medicine, 2021, 21, 450.	0.8	2
690	Insights into interplay of immunopathophysiological events and molecular mechanistic cascades in psoriasis and its associated comorbidities. Journal of Autoimmunity, 2021, 118, 102614.	3.0	24
691	Assessment of Serum Level of Claudinâ€3 and Its Association with Disease Severity in Patients with Psoriasis Vulgaris. The Egyptian Journal of Hospital Medicine, 2021, 83, 1155-1161.	0.0	2

#	Article	IF	CITATIONS
692	Features of the cytokine profile and the effectiveness of radical treatment of focal infection in patients with psoriasis. Vestnik Dermatologii I Venerologii, 2021, 97, 32-40.	0.2	3
693	CD137: A Member of the TNFR Family - in Psoriasis Skin Lesions in Comparison with Normal Skin Specimens. Iranian Journal of Pathology, 2021, 16, 103-108.	0.2	0
694	The Role of RhoH in TCR Signalling and Its Involvement in Diseases. Cells, 2021, 10, 950.	1.8	12
695	Discovery of a novel ROR \hat{I}^3 antagonist with skin-restricted exposure for topical treatment of mild to moderate psoriasis. Scientific Reports, 2021, 11, 9132.	1.6	12
696	Cyclin-Dependent Kinase 7 Promotes Th17/Th1 Cell Differentiation in Psoriasis by Modulating Glycolytic Metabolism. Journal of Investigative Dermatology, 2021, 141, 2656-2667.e11.	0.3	19
697	Dysregulation of the gut-brain-skin axis and key overlapping inflammatory and immune mechanisms of psoriasis and depression. Biomedicine and Pharmacotherapy, 2021, 137, 111065.	2.5	35
698	Crossing the boundaries: IL-23 and its role in linking inflammation of the skin, gut and joints. Rheumatology, 2021, 60, iv16-iv27.	0.9	11
699	Hallmarks of Aging in Macrophages: Consequences to Skin Inflammaging. Cells, 2021, 10, 1323.	1.8	30
700	Th17 Cells in Viral Infectionsâ€"Friend or Foe?. Cells, 2021, 10, 1159.	1.8	19
701	Integrated metabolomic analysis and cytokine profiling define clusters of immuno-metabolic correlation in new-onset psoriasis. Scientific Reports, 2021, 11, 10472.	1.6	14
702	miR‑489‑3p inhibits TLR4/NF‴κB signaling to prevent inflammation in psoriasis. Experimental and Therapeutic Medicine, 2021, 22, 744.	0.8	11
703	2′-Hydroxycinnamaldehyde ameliorates imiquimod-induced psoriasiform inflammation by targeting PKM2-STAT3 signaling in mice. Experimental and Molecular Medicine, 2021, 53, 875-884.	3.2	13
704	The Association Between Psoriasis and Cardiovascular Diseases. European Cardiology Review, 2021, 16, e19.	0.7	9
705	Dietary phytochemicals modulate intestinal epithelial barrier dysfunction and autoimmune diseases. Food Frontiers, 2021, 2, 357-382.	3.7	31
706	Brazilin downregulates CCL20 expression via regulation of STAT3 phosphorylation in TNF-α/IL-17A/IFN-Î3-induced HaCaT cells. Journal of Applied Biological Chemistry, 2021, 64, 185-192.	0.2	0
707	The paracaspase MALT1 in psoriasis. Biological Chemistry, 2021, 402, 1583-1589.	1.2	9
708	CD93 has a crucial role in pathogenesis of psoriasis. Journal of Cosmetic Dermatology, 2021, , .	0.8	4
709	Cross-talk between IFN- \hat{l}^3 and TWEAK through miR-149 amplifies skin inflammation in psoriasis. Journal of Allergy and Clinical Immunology, 2021, 147, 2225-2235.	1.5	29

#	ARTICLE	IF	CITATIONS
710	Key Signaling Pathways in Psoriasis: Recent Insights from Antipsoriatic Therapeutics. Psoriasis: Targets and Therapy, 2021, Volume 11, 83-97.	1.2	32
711	Psoriasis: To Vaccinate or Not to Vaccinate?. Cureus, 2021, 13, e15860.	0.2	O
712	Differential Changes in Inflammatory Mononuclear Phagocyte and T-Cell Profiles within Psoriatic Skin during Treatment with Guselkumab vs. Secukinumab. Journal of Investigative Dermatology, 2021, 141, 1707-1718.e9.	0.3	62
713	Evaluation of NLRP3 (rs10754558) and PTPN22 (1858C/T) (rs2476601) Functional Polymorphisms in Psoriasis Susceptibility in Egypt. The Application of Clinical Genetics, 2021, Volume 14, 331-339.	1.4	3
714	Mesenchymal stem cells derived from human dental follicle modulate the aberrant immune response in atopic dermatitis. Immunotherapy, 2021, 13, 825-840.	1.0	3
715	Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6Âmonths: A prospective analysis in Corrona Psoriasis Registry. Journal of the American Academy of Dermatology, 2022, 86, 68-76.	0.6	22
716	The RNase MCPIP3 promotes skin inflammation by orchestrating myeloid cytokine response. Nature Communications, 2021, 12, 4105.	5 . 8	14
717	Cellular nanovesicles with bioorthogonal targeting enhance photodynamic/photothermal therapy in psoriasis. Acta Biomaterialia, 2021, 134, 674-685.	4.1	17
718	IL-23/Th17 Axis: A Potential Therapeutic Target of Psoriasis. Current Drug Research Reviews, 2022, 14, 24-36.	0.7	14
719	MicroRNA-378a-3p is overexpressed in psoriasis and modulates cell cycle arrest in keratinocytes via targeting BMP2 gene. Scientific Reports, 2021, 11, 14186.	1.6	8
720	Association of Benzodiazepine Receptor Agonist Use With Changes in Psoriasis Severity in Adult Population: A Population-Based Study. Frontiers in Pharmacology, 2021, 12, 596375.	1.6	1
721	ACT1 Is Required for Murine IL-23–Induced Psoriasiform Inflammation Potentially Independent of E3 Ligase Activity. Journal of Investigative Dermatology, 2021, 141, 1772-1779.e6.	0.3	3
722	Natural medicine combined with nanobased topical delivery systems: a new strategy to treat psoriasis. Drug Delivery and Translational Research, 2021, , $1.$	3.0	4
723	IL-25 (IL-17E) in epithelial immunology and pathophysiology. Journal of Allergy and Clinical Immunology, 2021, 148, 40-52.	1.5	74
724	The role of LncRNA MALAT-1 and MiRNA-9 in Psoriasis. Biochemistry and Biophysics Reports, 2021, 26, 101030.	0.7	8
725	Experimental Pharmacological Management of Psoriasis. Journal of Experimental Pharmacology, 2021, Volume 13, 725-737.	1.5	15
726	Nano intervention in topical delivery of corticosteroid for psoriasis and atopic dermatitisâ€"a systematic review. Journal of Materials Science: Materials in Medicine, 2021, 32, 88.	1.7	20
727	Anoctamin1 Induces Hyperproliferation of HaCaT Keratinocytes and Triggers Imiquimod-Induced Psoriasis-Like Skin Injury in Mice. International Journal of Molecular Sciences, 2021, 22, 7145.	1.8	8

#	Article	IF	CITATIONS
728	Enhanced uptake and anti-maturation effect of celastrol-loaded mannosylated liposomes on dendritic cells for psoriasis treatment. Acta Pharmaceutica Sinica B, 2022, 12, 339-352.	5.7	40
729	<scp>IL</scp> â€36α and <scp>IL</scp> â€36γ expressions in the differential diagnosis of palmoplantar psoriasis and palmoplantar eczema: A retrospective histopathologic and immunohistochemical study. Journal of Cutaneous Pathology, 2022, 49, 42-48.	0.7	3
730	Survey and Comparative Study on Treatment of Psoriasis. International Journal of Pharmaceutical Sciences Review and Research, 2021, 69, .	0.1	0
731	Adiponectin in psoriasis and its comorbidities: a review. Lipids in Health and Disease, 2021, 20, 87.	1.2	11
732	The STING antagonist Hâ€151 ameliorates psoriasis via suppression of STING/NFâ€Pâêmediated inflammation. British Journal of Pharmacology, 2021, 178, 4907-4922.	2.7	32
733	SnapshotDx Quiz: August 2021. Journal of Investigative Dermatology, 2021, 141, e87-e92.	0.3	0
734	Population pharmacokinetic and exposure–response analysis of apremilast in Japanese subjects with moderate to severe psoriasis. Journal of Dermatology, 2021, 48, 1652-1664.	0.6	2
735	Involvement of miR-214-3p/FOXM1 Axis During the Progression of Psoriasis. Inflammation, 2022, 45, 267-278.	1.7	9
736	Dendritic Cells and CCR7 Expression: An Important Factor for Autoimmune Diseases, Chronic Inflammation, and Cancer. International Journal of Molecular Sciences, 2021, 22, 8340.	1.8	42
737	Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis. Nature Communications, 2021, 12, 4741.	5.8	23
738	Development and Characterization of a Clobetasol Propionate Nanostructured Lipid Carrier-Based Gel for the Treatment of Plaque Psoriasis. Current Molecular Pharmacology, 2021, 14, 399-411.	0.7	3
739	Mitochondrial Reactive Oxygen Species Are Essential for the Development of Psoriatic Inflammation. Frontiers in Immunology, 2021, 12, 714897.	2.2	24
740	Optical control of adenosine A3 receptor function in psoriasis. Pharmacological Research, 2021, 170, 105731.	3.1	7
741	Apremilast downregulates interleukin-17 production and induces splenic regulatory B cells and regulatory T cells in imiquimod-induced psoriasiform dermatitis. Journal of Dermatological Science, 2021, 104, 55-62.	1.0	O
742	Extra-Articular Manifestations and Comorbidities in Psoriatic Disease: A Journey Into the Immunologic Crosstalk. Frontiers in Medicine, 2021, 8, 737079.	1.2	14
743	Serum profiles of tryptophan-kynurenine pathway metabolites in psoriasis. Exploration of Immunology, 0, , .	1.7	2
744	Newâ€onset and exacerbations of psoriasis after mRNA COVIDâ€19 vaccines: two sides of the same coin?. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	20
745	Pustular psoriasis and arthropathy in a patient with HIV infection. Clinical case. Russian Journal of Skin and Venereal Diseases, 2021, 24, 151-160.	0.0	O

#	Article	IF	CITATIONS
746	Circulating Metabolomic Signature in Generalized Pustular Psoriasis Blunts Monocyte Hyperinflammation by Triggering Amino Acid Response. Frontiers in Immunology, 2021, 12, 739514.	2.2	7
747	miR-21-3p/IL-22 Axes Are Major Drivers of Psoriasis Pathogenesis by Modulating Keratinocytes Proliferation-Survival Balance and Inflammatory Response. Cells, 2021, 10, 2547.	1.8	10
748	Cytosolic DNAâ€'Mediated STING-Dependent Inflammation Contributes to the Progression of Psoriasis. Journal of Investigative Dermatology, 2022, 142, 898-906.e4.	0.3	13
749	Repurposing the anthelmintic praziquantel to treat psoriasis. British Journal of Pharmacology, 2021, 178, 4726-4740.	2.7	6
750	Capsaicin attenuates imiquimod-induced epidermal hyperplasia and cutaneous inflammation in a murine model of psoriasis. Biomedicine and Pharmacotherapy, 2021, 141, 111950.	2.5	13
752	Analytical approaches to assess metabolic changes in psoriasis. Journal of Pharmaceutical and Biomedical Analysis, 2021, 205, 114359.	1.4	8
753	Modular pharmacology-based approach to identify hub genes and kernel pathways of taodan granules treated psoriasis. Journal of Ethnopharmacology, 2021, 280, 114485.	2.0	4
7 54	A Sensitization-Free Dimethyl Fumarate Prodrug, Isosorbide Di-(Methyl Fumarate), Provides a Topical Treatment Candidate for Psoriasis. JID Innovations, 2021, 1, 100040.	1.2	8
755	Biological action of docosahexaenoic acid in a 3D tissue-engineered psoriatic skin model: Focus on the PPAR signaling pathway. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2021, 1866, 159032.	1.2	9
756	Neurokinin receptors and their implications in various autoimmune diseases. Current Research in Immunology, 2021, 2, 66-78.	1.2	12
757	Immune responses and therapeutic options in psoriasis. Cellular and Molecular Life Sciences, 2021, 78, 2709-2727.	2.4	25
758	Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities. Dermatology and Therapy, 2021, 11, 385-400.	1.4	29
759	Risk of chronic kidney disease and end-stage renal disease in patients with psoriasis: A systematic review and meta-analysis of cohort studies. Dermatologica Sinica, 2021, 39, 19.	0.2	12
760	Neuro-dermatological association between psoriasis and depression: an immune-mediated inflammatory process validating skin-brain axis theory. AIMS Neuroscience, 2021, 8, 340-354.	1.0	8
761	Gamma-Delta T Cells in the Skin. , 2017, , 51-66.		1
763	Targeted Therapies and Biomarkers for Personalized Treatment of Psoriasis. , 2015, , 77-100.		2
764	Discovering the genes mediating the interactions between chronic respiratory diseases in the human interactome. Nature Communications, 2020, 11, 811.	5.8	25
765	Double-negative T cells in autoimmune diseases. Current Opinion in Rheumatology, 2021, 33, 163-172.	2.0	34

#	Article	IF	CITATIONS
768	Epithelial TRAF6 drives IL-17–mediated psoriatic inflammation. JCI Insight, 2018, 3, .	2.3	36
769	Keratinocyte-derived llºBl¶ drives psoriasis and associated systemic inflammation. JCl Insight, 2019, 4, .	2.3	24
770	The CDK4/6-EZH2 pathway is a potential therapeutic target for psoriasis. Journal of Clinical Investigation, 2020, 130, 5765-5781.	3.9	29
771	RAC1 activation drives pathologic interactions between the epidermis and immune cells. Journal of Clinical Investigation, 2016, 126, 2661-2677.	3.9	48
772	Expression of NLPR3 in Psoriasis Is Associated with Enhancement of Interleukin- $1\hat{l}^2$ and Caspase-1. Medical Science Monitor, 2018, 24, 7909-7913.	0.5	36
773	Psoriatic arthritis. F1000Research, 2019, 8, 1665.	0.8	105
774	Psoriasis is characterized by deficient negative immune regulation compared to transient delayed-type hypersensitivity reactions. F1000Research, 2015, 4, 149.	0.8	15
775	Deep Sequencing of the T-cell Receptor Repertoire Demonstrates Polyclonal T-cell Infiltrates in Psoriasis. F1000Research, 2015, 4, 460.	0.8	40
776	Solving the puzzle of autoimmunity: critical questions. F1000prime Reports, 2015, 7, 17.	5.9	7
777	Keratinocyte Detachment-Differentiation Connection Revisited, or Anoikis-Pityriasi Nexus Redux. PLoS ONE, 2014, 9, e100279.	1.1	12
778	CARD14 Expression in Dermal Endothelial Cells in Psoriasis. PLoS ONE, 2014, 9, e111255.	1.1	52
779	Cytosolic RNA:DNA Duplexes Generated by Endogenous Reverse Transcriptase Activity as Autonomous Inducers of Skin Inflammation in Psoriasis. PLoS ONE, 2017, 12, e0169879.	1.1	11
780	Going, Toll-like receptors in skin inflammation and inflammatory diseases. EXCLI Journal, 2021, 20, 52-79.	0.5	10
781	SOCS3 inhibits the pathological effects of IL-22 in non-melanoma skin tumor-derived keratinocytes. Oncotarget, 2017, 8, 24652-24667.	0.8	19
782	Treatment of Psoriasis: A Comprehensive Review of Entire Therapies. Current Drug Safety, 2020, 15, 82-104.	0.3	38
783	The Association of Metabolic Syndrome and Psoriasis: A Systematic Review and Meta-Analysis of Observational Study. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2020, 20, 703-717.	0.6	34
784	The Psoriasis Pathogenesis and the Metabolic Risk. Open Dermatology Journal, 2018, 12, 70-79.	0.5	1
785	The Woronoff Ring in Psoriasis and the Mechanisms of Postinflammatory Hypopigmentation. Acta Dermato-Venereologica, 2020, 100, 66-69.	0.6	7

#	Article	IF	Citations
786	Psoriasis and the TNF/IL23/IL17 axis. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 418-424.	0.8	50
787	Moderate-to-severe psoriasis and pregnancy: impact on fertility, pregnancy outcome and treatment perspectives. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 305-314.	0.8	19
788	New JAK inhibitors for the treatment of psoriasis and psoriatic arthritis. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 411-420.	0.8	8
789	Efficacy and Safety of BCD-085, a Novel Interleukin-17 Inhibitor. Results of Phase II Clinical Trial in Patients with Moderate-to-Severe Plaque Psoriasis. Vestnik Dermatologii I Venerologii, 2017, , 52-63.	0.2	15
790	IL-36 signaling in keratinocytes controls early IL-23 production in psoriasis-like dermatitis. Life Science Alliance, 2020, 3, e202000688.	1.3	37
791	Skin and Gut Microbiome in Psoriasis: Gaining Insight Into the Pathophysiology of It and Finding Novel Therapeutic Strategies. Frontiers in Microbiology, 2020, 11, 589726.	1.5	81
792	2-deoxy-d-glucose Ameliorates Animal Models of Dermatitis. Biomedicines, 2020, 8, 20.	1.4	14
793	Ustekinumab: "Real-world―outcomes and potential predictors of nonresponse in treatment-refractory Crohn's disease. World Journal of Gastroenterology, 2019, 25, 4481-4492.	1.4	34
794	Transcriptomic landscaping of core genes andÂpathways of mild and severe psoriasis vulgaris. International Journal of Molecular Medicine, 2020, 47, 219-231.	1.8	17
795	lκB-ζ Expression Requires Both TYK2/STAT3 Activity and IL-17–Regulated mRNA Stabilization. ImmunoHorizons, 2019, 3, 172-185.	0.8	17
796	Positive-Negative Feedback Loop between Mir-197 and IL-17A Signaling in Human Keratinocytes. Immunome Research, 2016, 12, .	0.1	5
797	Interleukin 22 and 6 serum concentrations decrease under long-term biologic therapy in psoriasis. Postepy Dermatologii I Alergologii, 2020, 37, 705-711.	0.4	11
798	Pyruvate Kinase M2 Mediates Glycolysis Contributes to Psoriasis by Promoting Keratinocyte Proliferation. Frontiers in Pharmacology, 2021, 12, 765790.	1.6	19
799	Cudraxanthone D Ameliorates Psoriasis-like Skin Inflammation in an Imiquimod-Induced Mouse Model via Inhibiting the Inflammatory Signaling Pathways. Molecules, 2021, 26, 6086.	1.7	6
800	Cutaneous Inflammation: Prototypes of Immunological Mechanisms Involving the Skin., 2022, , 161-216.		0
801	A long way to go: caspase inhibitors in clinical use. Cell Death and Disease, 2021, 12, 949.	2.7	57
802	Application of benvitimod on psoriasis: A systematic review and meta-analysis of randomized controlled trials. A systematic review of benvitimod on psoriasis. Therapie, 2021, , .	0.6	1
803	Methodological shortcomings in the reports of the imiquimod psoriatic model. Experimental Dermatology, 2022, 31, 299-303.	1.4	1

#	Article	IF	CITATIONS
804	First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of LANCL2 pathway in psoriasis. Scientific Reports, 2021, 11, 19827.	1.6	6
805	Gomisin M2 alleviates psoriasisâ€'like skin inflammation by inhibiting inflammatory signaling pathways. Molecular Medicine Reports, 2021, 24, .	1.1	3
806	Discovery of 2-(Ortho-Substituted Benzyl)-Indole Derivatives as Potent and Orally Bioavailable RORÎ ³ Agonists with Antitumor Activity. Journal of Medicinal Chemistry, 2021, 64, 14983-14996.	2.9	5
807	Cav1.4 calcium channels control cytokine production by human peripheral TH17 cells and psoriatic skin-infiltrating T cells. Journal of Allergy and Clinical Immunology, 2021, , .	1.5	2
808	Dendritic Cells. , 2015, , 1-11.		0
809	Mechanisms of Bone Remodelling in Psoriatic Arthritis. , 2016, , 111-126.		0
810	Innate and Acquired Cellular Immune Responses in Psoriasis and Psoriatic Arthritis., 2016,, 61-72.		0
811	Dendritic Cells. , 2016, , 439-448.		0
812	Ixekizumab. , 2016, , 153-162.		0
813	The study of the specific pharmacological activity of Dermabin on the model of the experimental contact dermatitis in rats. Clinical Pharmacy, 2016, 20, 30-34.	0.2	0
814	T Cell Immune Responses in Skin. , 2017, , 121-135.		0
815	Pustulosis palmaris et plantaris: pathogenetic, clinical, and epidemiological features. Klinicheskaya Dermatologiya I Venerologiya, 2017, 16, 4.	0.0	1
816	Differential Roles of the mTOR-STAT3 Signaling in Dermal $\hat{I}^3\hat{I}$ T Cell Effector Function in Skin Inflammation. SSRN Electronic Journal, 0 , , .	0.4	0
817	Diabetes and the Skin. Endocrinology, 2018, , 437-450.	0.1	0
818	Role of Gut Microbiota inÂlmmune Homeostasis. , 2018, , 135-154.		1
819	Paradoxical psoriasiform inflammatory reaction during the use of tumor necrosis factor-alpha inhibitors in patients with Crohn's disease (a review of the literature and presentation of two) Tj ETQq1 1 0.3	78 431 4 rg	:BT ¢ Overlock
821	Psoriatic Arthritis and Infection. , 2019, , 393-397.		0
822	Diabetes and the Skin. Endocrinology, 2019, , 1-14.	0.1	0

#	Article	IF	Citations
824	Possible role of BMPâ€'4 in the hyperâ€'pigmentation of psoriatic plaques after antiâ€'TNFâ€'α treatment. Experimental and Therapeutic Medicine, 2019, 18, 4120-4124.	0.8	5
825	Inflammatory marker alteration in response to systemic therapies in psoriasis. Experimental and Therapeutic Medicine, 2020, 20, 42-46.	0.8	9
826	Mechanisms of innate immunity in pathogenesis of psoriasis: approaches to targeted therapy. Medical Immunology (Russia), 2020, 22, 449-458.	0.1	0
828	â€~Psoriasis�1' reduces Tâ€ʻlymphocyteâ€ʻmediated inflammation in patients with psoriasis by inhibiting vitamin�D receptorâ€ʻmediated STAT4 inactivation. International Journal of Molecular Medicine, 2020, 46, 1538-1550.	1.8	4
829	Current Concepts of Psoriasis Immunopathogenesis. International Journal of Molecular Sciences, 2021, 22, 11574.	1.8	52
830	Maximizing the Utility of Transcriptomics Data in Inflammatory Skin Diseases. Frontiers in Immunology, 2021, 12, 761890.	2.2	9
831	Inhibition of keratinocyte ferroptosis suppresses psoriatic inflammation. Cell Death and Disease, 2021, 12, 1009.	2.7	70
832	Lack of evidence for expression and function of IL-39 in human immune cells. PLoS ONE, 2020, 15, e0242329.	1.1	13
833	Innate lymphoid cells in autoimmune diseases. , 2022, , 143-175.		2
834	Diabetes and the Skin. Endocrinology, 2020, , 437-450.	0.1	0
835	Psoriasis: A Comprehensive Review on the Aetiopathogenesis and Recent Advances in Long-Term Management of Patients with Plaque Psoriasis. Pharmacology & Pharmacy, 2020, 11, 373-401.	0.2	0
836	The impact of vitamin D deficiency and microbiome in psoriasis versus non immune-mediated diseases. Journal of Dermatology & Cosmetology, 2020, 4, 162-165.	0.1	O
837	Optimal Strategies of the Psoriasis Treatment by Suppressing the Interaction Between T-Lymphocytes and Dendritic Cells. Springer Proceedings in Mathematics and Statistics, 2020, , 1-11.	0.1	0
838	Cutaneous Inflammation: Prototypes of Immunological Mechanisms Involving the Skin., 2020, , 1-56.		0
839	The Epigenetic Basis of Loss of Tolerance. , 2020, , 87-101.		0
840	MicroRNA-148a facilitates inflammatory dendritic cell differentiation and autoimmunity by targeting MAFB. JCI Insight, 2020, 5, .	2.3	14
841	Environmental, inflammatory, and antiâ€inflammatory squad in acne vulgaris pathogenesis: AhR, ILâ€36, and ILâ€38. Journal of Cosmetic Dermatology, 2021, , .	0.8	2
842	HSP90 inhibitor RGRNâ€305 for oral treatment of plaqueâ€type psoriasis: efficacy, safety and biomarker results in an openâ€label proofâ€ofâ€concept study*. British Journal of Dermatology, 2022, 186, 861-874.	1.4	19

#	Article	IF	CITATIONS
843	Use of Cytokine Mix-, Imiquimod-, and Serum-Induced Monoculture and Lipopolysaccharide- and Interferon Gamma-Treated Co-Culture to Establish In Vitro Psoriasis-like Inflammation Models. Cells, 2021, 10, 2985.	1.8	2
844	Curcumin and ustekinumab cotherapy alleviates induced psoriasis in rats through their antioxidant, anti-inflammatory, and antiproliferative effects. Cutaneous and Ocular Toxicology, 2022, 41, 33-42.	0.5	3
845	Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 400-410.	0.8	9
847	Systemic treatment of psoriasis: from methotrexate to biologics. Vestnik Dermatologii I Venerologii, 2020, 96, 7-26.	0.2	6
848	Elucidating new drug targets in psoriasis by gene profiling: an opportunity to be seized. Annals of Translational Medicine, 2015, 3, 78.	0.7	0
849	The Role of IL-17 in the Pathogenesis and Treatment of Psoriasis. Journal of Clinical and Aesthetic Dermatology, 2016, 9, S3-S6.	0.1	27
850	Systemic Immune-Inflammation Index (SII) Predicts Increased Severity in Psoriasis and Psoriatic Arthritis. Current Health Sciences Journal, 2020, 46, 352-357.	0.2	5
851	Consider the chemokines: a review of the interplay between chemokines and T cell subset function. Discovery Medicine, 2017, 24, 31-39.	0.5	19
852	Interplay Between Skin Microbiota Dysbiosis and the Host Immune System in Psoriasis: Potential Pathogenesis. Frontiers in Immunology, 2021, 12, 764384.	2.2	19
853	Leucosceptoside A from Devil's Claw Modulates Psoriasis-like Inflammation via Suppression of the PI3K/AKT Signaling Pathway in Keratinocytes. Molecules, 2021, 26, 7014.	1.7	5
854	CD8αα ⁺ T cells exert a proâ€inflammatory role in patients with psoriasis. Skin Health and Disease, 2021, 1, e64.	0.7	2
855	Keratinocyte-intrinsic BCL10/MALT1 activity initiates and amplifies psoriasiform skin inflammation. Science Immunology, 2021, 6, eabi4425.	5.6	5
856	Body Mass Index Influence for the Personalization of the Monoclonal Antibodies Therapy for Psoriasis. Life, 2021, 11, 1316.	1.1	3
857	Adipose-derived mesenchymal stem cells (AD-MSCs) in the treatment for psoriasis: results of a single-arm pilot trial. Annals of Translational Medicine, 2021, 9, 1653-1653.	0.7	4
858	Efficacy and Safety of Different Formulations of Calcipotriol/Betamethasone Dipropionate in Psoriasis: Gel, Foam, and Ointment. Journal of Clinical Medicine, 2021, 10, 5589.	1.0	9
860	NF-κB1 Contributes to Imiquimod-Induced Psoriasis-Like Skin Inflammation by Inducing Vγ4+Vδ4+γÎT17 Cells. Journal of Investigative Dermatology, 2022, 142, 1639-1649.e5.	0.3	2
861	Logical and experimental modeling of cytokine and eicosanoid signaling in psoriatic keratinocytes. IScience, 2021, 24, 103451.	1.9	7
862	A Traditional Chinese Medicine Formula Danshen Baibixiao Ameliorates Imiquimod-Induced Psoriasis-Like Inflammation in Mice. Frontiers in Pharmacology, 2021, 12, 749626.	1.6	5

#	Article	IF	CITATIONS
863	Genetic variants in IL-17A rs 10484879 and serum levels of IL-17A are associated with psoriasis risk. Archives of Dermatological Research, 2021 , , 1 .	1.1	3
864	Serum interleukin-17 predicts severity and prognosis in patients with community acquired pneumonia: a prospective cohort study. BMC Pulmonary Medicine, 2021, 21, 393.	0.8	12
865	Relationship between mir-126 expression in children with psoriasis, disease progression and therapeutic response. Journal of Medicine and Life, 2021, 14, 667-675.	0.4	0
866	Evaluation of cytokine gene expression in psoriasis. Postepy Dermatologii I Alergologii, 2021, 38, 858-863.	0.4	4
867	Therapeutic potential of targeting interleukinâ€1 family cytokines in chronic inflammatory skin diseases*. British Journal of Dermatology, 2022, 186, 925-941.	1.4	29
869	Perillyl alcohol inhibits keratinocyte proliferation and attenuates imiquimod-induced psoriasis like skin-inflammation by modulating NF-κB and STAT3 signaling pathways. International Immunopharmacology, 2022, 103, 108436.	1.7	15
870	Synthesis of novel thiazolidinic-phthalimide derivatives evaluated as new multi-target antiepileptic agents. Bioorganic Chemistry, 2022, 119, 105548.	2.0	6
871	Disclosing the involvement of proteases in an eczema murine animal model: Perspectives for protease inhibitor-based therapies. Biochimie, 2022, 194, 1-12.	1.3	2
872	Vitamin D serum levels in children with psoriasis. Ukrainian Journal of Dermatology Venerology Cosmetology, 2020, .	0.0	0
873	Detection of Some Immunological Parameters in Psoriatic Iraqi Female Patients. Iraqi Journal of Science, 0, , 2515-2524.	0.3	0
874	The Role of Nutrition in Immune-Mediated, Inflammatory Skin Disease: A Narrative Review. Nutrients, 2022, 14, 591.	1.7	10
875	Genisteinâ€"Opportunities Related to an Interesting Molecule of Natural Origin. Molecules, 2022, 27, 815.	1.7	15
876	Exosomes Derived from Human Umbilical Cord Mesenchymal Stem Cells Alleviate Psoriasis-like Skin Inflammation. Journal of Interferon and Cytokine Research, 2022, 42, 8-18.	0.5	23
877	Effects of different concentrations of human umbilical cord mesenchymal stem cells to ameliorate psoriasis-like skin lesions in BALB/c mice. Annals of Translational Medicine, 2022, 10, 86-86.	0.7	3
878	Involvement of Th1Th17 Cell Subpopulations in the Immune Responses of Mothers Who Gave Birth to Children with Congenital Zika Syndrome (CZS). Viruses, 2022, 14, 250.	1.5	1
879	Netakimab in treatment of moderate to severe forms of psoriasis. Medical Alphabet, 2022, , 17-19.	0.0	0
880	Prevalence of autoimmune thyroid disease in patients with psoriasis: a meta-analysis. BMJ Open, 2022, 12, e055538.	0.8	5
881	Cytoplasmic RNA quality control failure engages mTORC1-mediated autoinflammatory disease. Journal of Clinical Investigation, 2022, 132, .	3.9	9

#	Article	IF	Citations
883	Acitretin-Conjugated Dextran Nanoparticles Ameliorate Psoriasis-like Skin Disease at Low Dosages. Frontiers in Bioengineering and Biotechnology, 2021, 9, 816757.	2.0	4
884	Therapeutic Application of Microsponges-based Drug Delivery Systems. Current Pharmaceutical Design, 2022, 28, 595-608.	0.9	2
885	SIDT1 plays a key role in type I IFN responses to nucleic acids in plasmacytoid dendritic cells and mediates the pathogenesis of an imiquimod-induced psoriasis model. EBioMedicine, 2022, 76, 103808.	2.7	10
886	Celastrol gel ameliorates imiquimod-induced psoriasis-like dermatitis in mice by targeting Langerhans cells. Biomedicine and Pharmacotherapy, 2022, 147, 112644.	2.5	11
887	The Gut Microbiome in Psoriasis and Crohnâ∈™s Disease: Is Its Perturbation a Common Denominator for Their Pathogenesis?. Vaccines, 2022, 10, 244.	2.1	13
888	Antigen-Presenting Cells in Psoriasis. Life, 2022, 12, 234.	1.1	6
889	Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies. Psoriasis: Targets and Therapy, 2021, Volume 11, 151-168.	1.2	10
890	Goeckerman Regimen Reduces Alarmin Levels and PASI Score in Paediatric Patients with Psoriasis. Acta Medica (Hradec Kralove), 2021, 64, 204-212.	0.2	0
891	Research Progress on the Correlation between Skin Microbiome and Pathogenesis of Psoriasis. Advances in Clinical Medicine, 2022, 12, 1248-1254.	0.0	0
892	Immunogenetics and its utility in therapeutics. , 2022, , 1-34.		0
893	Targeting the Epithelium-Derived Innate Cytokines: From Bench to Bedside. Immune Network, 2022, 22, e11.	1.6	14
894	Exosomes and Other Extracellular Vesicles with High Therapeutic Potential: Their Applications in Oncology, Neurology, and Dermatology. Molecules, 2022, 27, 1303.	1.7	20
895	Angiotensin-Converting Enzyme Activity May Predict Disease Severity in Psoriasis. Rheumato, 2022, 2, 15-23.	0.2	1
896	Immune Markers in Psoriasis. , 0, , .		0
897	Selenium-Rich Yeast Peptide Fraction Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis in Mice by Inhibiting Inflammation via MAPK and NF-κB Signaling Pathways. International Journal of Molecular Sciences, 2022, 23, 2112.	1.8	8
898	Severe Itchy Extensive Psoriasis Vulgaris Provoked by Tramadol. Journal of Skin and Stem Cell, 2022, 8,	0.1	0
899	Cytokine induced 3â€D organotypic psoriasis skin model demonstrates distinct roles for NFâ€PB and JAK pathways in disease pathophysiology. Experimental Dermatology, 2022, 31, 1036-1047.	1.4	6
900	Anti-psoriatic effects of tetrahydrocurcumin lipidic nanoparticles in IMQ induced psoriatic plaque: A research report. Journal of Drug Delivery Science and Technology, 2022, , 103301.	1.4	1

#	ARTICLE	IF	CITATIONS
901	Chromatin accessibility and transcriptome integrative analysis revealed AP-1-mediated genes potentially modulate histopathology features in psoriasis. Clinical Epigenetics, 2022, 14, 38.	1.8	6
902	Jatrophane Diterpenoids with Kv1.3 Ion Channel Inhibitory Effects from <i>Euphorbia helioscopia</i> Journal of Natural Products, 2022, 85, 815-827.	1.5	7
903	Recent Advancements in Antipsoriatic Therapy: An Update. , 0, , 83-108.		1
904	IL-17A Promotes Psoriasis-Associated Keratinocyte Proliferation through ACT1-Dependent Activation of YAP–AREG Axis. Journal of Investigative Dermatology, 2022, 142, 2343-2352.	0.3	15
905	IL-22 Plays a Dual Role in the Amniotic Cavity: Tissue Injury and Host Defense against Microbes in Preterm Labor. Journal of Immunology, 2022, 208, 1595-1615.	0.4	11
906	Relationship between Immune Cells, Depression, Stress, and Psoriasis: Could the Use of Natural Products Be Helpful?. Molecules, 2022, 27, 1953.	1.7	33
907	Psoriasis and osteoporosis: a literature review. Clinical and Experimental Dermatology, 2022, 47, 1438-1445.	0.6	9
908	Hot on the Trail of Skin Inflammation: Focus on TRPV1/TRPV3 Channels in Psoriasis. Biochemistry, 0, , .	0.8	1
909	From Empirical to Pathogenesis-Based Treatments for Psoriasis. Journal of Investigative Dermatology, 2022, 142, 1778-1785.	0.3	28
910	Chemistry, pharmacokinetics, pharmacological activities, and toxicity of Quercitrin. Phytotherapy Research, 2022, 36, 1545-1575.	2.8	42
911	The Relapse of Psoriasis: Mechanisms and Mysteries. JID Innovations, 2022, 2, 100116.	1.2	37
912	Decosus: An R Framework for Universal Integration of Cell Proportion Estimation Methods. Frontiers in Genetics, 2022, 13, 802838.	1.1	3
913	Identification of Cell Markers and Their Expression Patterns in Skin Based on Single-Cell RNA-Sequencing Profiles. Life, 2022, 12, 550.	1.1	24
914	The effectiveness of synthetic methoxylated isoflavones in delivering to the skin and alleviating psoriasiform lesions via topical absorption. International Journal of Pharmaceutics, 2022, 617, 121629.	2.6	3
915	The biological basis of disease recurrence in psoriasis: a historical perspective and current models. British Journal of Dermatology, 2022, 186, 773-781.	1.4	32
916	A Hairy Cituation – PADIs in Regeneration and Alopecia. Frontiers in Cell and Developmental Biology, 2021, 9, 789676.	1.8	5
917	Psychological Stress, Mast Cells, and Psoriasisâ€"Is There Any Relationship?. International Journal of Molecular Sciences, 2021, 22, 13252.	1.8	11
918	Astragalus mongholicus Bunge Water Extract Exhibits Anti-inflammatory Effects in Human Neutrophils and Alleviates Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice. Frontiers in Pharmacology, 2021, 12, 762829.	1.6	8

#	Article	IF	CITATIONS
919	The Role of Helper T Cells in Psoriasis. Frontiers in Immunology, 2021, 12, 788940.	2.2	70
920	Crosstalk between keratinocytes and immune cells in inflammatory skin diseases. Exploration of Immunology, 0, , 418-431.	1.7	8
921	Targeted therapies and precision medicine for inflammatory skin diseases. European Journal of Dermatology, 2019, 29, 19-24.	0.3	2
922	Chronic inflammation, insulin resistance, psoriasis - which have in common?. Vestnik Dermatologii I Venerologii, 2016, 92, 20-24.	0.2	2
923	Frequency of genotypes and allelic polymorphisms of Vitamin D receptor in egyptian psoriatic patients and their association with disease severity, immune modulation of IL-22 levels and the response to topical calcipotriol treatment: A case control study. Indian Journal of Dermatology, 2022, 67, 37.	0.1	2
924	Effect of Melatonin on Psoriatic Phenotype in Human Reconstructed Skin Model. Biomedicines, 2022, 10, 752.	1.4	4
925	Value of PASI90 Versus Merit-Based Incentive Payment System Efficacy Measures. Journal of Psoriasis and Psoriatic Arthritis, 0, , 247553032210826.	0.3	0
926	Therapeutic effects of the extract of sancao formula, a chinese herbal compound, on imiquimod-induced psoriasis via cysteine-rich protein 61. Journal of Integrative Medicine, 2022, , .	1.4	0
954	Ligustrazine alleviates psoriasis-like inflammation through inhibiting TRAF6/c-JUN/NFκB signaling pathway in keratinocyte. Biomedicine and Pharmacotherapy, 2022, 150, 113010.	2.5	10
957	CHRNA5 Is Overexpressed in Patients with Psoriasis and Promotes Psoriasis-Like Inflammation in Mouse Models. Journal of Investigative Dermatology, 2022, 142, 2978-2987.e6.	0.3	6
958	Updated Perspectives on Keratinocytes and Psoriasis: Keratinocytes are More Than Innocent Bystanders. Psoriasis: Targets and Therapy, 2022, Volume 12, 73-87.	1.2	20
959	Synthesis and In-Vivo Evaluation of Benzoxazole Derivatives as Promising Anti-Psoriatic Drugs for Clinical Use. Molecules, 2022, 27, 3023.	1.7	4
960	The Protective Role of pVHL in Imiquimod-Induced Psoriasis-like Skin Inflammation. International Journal of Molecular Sciences, 2022, 23, 5226.	1.8	4
961	ILF2 Contributes to Hyperproliferation of Keratinocytes and Skin Inflammation in a KLHDC7B-DT-Dependent Manner in Psoriasis. Frontiers in Genetics, 2022, 13, 890624.	1.1	11
962	Dextromethorphan Exhibits Anti-Inflammatory and Immunomodulatory Effects in a Murine Model: Therapeutic Implication in Psoriasis. Life, 2022, 12, 696.	1.1	0
963	3, 3′- diindolylmethane hinders IL-17A/IL-17RA interaction and mitigates imiquimod-induced psoriasiform in mice. International Immunopharmacology, 2022, 109, 108795.	1.7	2
964	Inflammation and itching in patients suffering from atopic dermatitis and psoriasis. Assessment of the expression of neurotrophins аnd neuropeptides. Vestnik Dermatologii I Venerologii, 2014, 90, 77-85.	0.2	1
965	Assessment of Psoriatic Skin Features Using Non-Invasive Imaging Technique. Processes, 2022, 10, 985.	1.3	4

#	Article	IF	CITATIONS
966	NF-κB: A Double-Edged Sword Controlling Inflammation. Biomedicines, 2022, 10, 1250.	1.4	35
967	Based on Gene Expression Analysis: Low-Density Neutrophil Expression Is a Characteristic of the Fast Responders Treated With Guselkumab for Psoriasis. Frontiers in Immunology, 2022, 13, .	2.2	5
968	ZNF384: A Potential Therapeutic Target for Psoriasis and Alzheimerâ \in TM s Disease Through Inflammation and Metabolism. Frontiers in Immunology, 0, 13, .	2.2	7
969	Members of the Regulatory Lymphocyte Club in Common Variable Immunodeficiency. Frontiers in Immunology, 2022, 13, .	2.2	6
970	Real life longâ€term efficacy and safety of ixekizumab in moderateâ€toâ€severe psoriasis: A 192 weeks multicentric retrospective study— <scp>IL PSO</scp> (<scp>Italian</scp> landscape psoriasis). Dermatologic Therapy, 2022, 35, .	0.8	10
971	Psoriasis and Cardiovascular Diseases: An Immune-Mediated Cross Talk?. Frontiers in Immunology, 2022, 13, .	2.2	10
972	Deep Sequencing of Plasma Exosomal microRNA Level in Psoriasis Vulgaris Patients. Frontiers in Medicine, $0,9,.$	1.2	3
973	A Modified Hyaluronic Acid–Based Dissolving Microneedle Loaded With Daphnetin Improved the Treatment of Psoriasis. Frontiers in Bioengineering and Biotechnology, 2022, 10, .	2.0	8
974	Newâ€onset guttate psoriasis following coronavirus disease 2019 vaccination: About two cases. Dermatologic Therapy, 2022, 35, .	0.8	5
975	Aloperine Ameliorates IMQ-Induced Psoriasis by Attenuating Th17 Differentiation and Facilitating Their Conversion to Treg. Frontiers in Pharmacology, 2022, 13, .	1.6	1
976	Enhancing the anti-psoriatic activity of vitamin D3 employing nanostructured archaeolipid carriers. Journal of Drug Delivery Science and Technology, 2022, 73, 103455.	1.4	2
977	Long-Acting \hat{I}^22 Adrenergic Receptor Agonist Ameliorates Imiquimod-Induced Psoriasis-Like Skin Lesion by Regulating Keratinocyte Proliferation and Apoptosis. Frontiers in Pharmacology, 0, 13, .	1.6	2
978	Oversight and Management of Women with Psoriasis in Childbearing Age. Medicina (Lithuania), 2022, 58, 780.	0.8	1
979	Sprouty1 exerts a preventive effect on the initiation of psoriasis by inhibiting innate immune antimicrobial peptide cathelicidin and immunocytes. Cell Proliferation, 2022, 55, .	2.4	3
980	Molecular and cellular regulation of psoriatic inflammation. Clinical Science, 2022, 136, 935-952.	1.8	1
981	Langerhans cells are an essential cellular intermediary in chronic dermatitis. Cell Reports, 2022, 39, 110922.	2.9	5
982	New-onset systemic lupus erythematous in a patient receiving risankizumab for psoriasis. JAAD Case Reports, 2022, 25, 104-106.	0.4	2
983	Intravenous As ₂ O ₃ as a promising treatment for psoriasis â€" an experimental study in psoriasis-like mouse model. Immunopharmacology and Immunotoxicology, 2022, 44, 935-958.	1.1	1

#	ARTICLE	IF	CITATIONS
984	Identification of key apoptosis-related genes and immune infiltration in the pathogenesis of psoriasis. Hereditas, 2022, 159, .	0.5	3
985	Treatment of chronic plaque psoriasis with herbal Unani formulations: A randomized control trial of efficacy and safety. Journal of Ethnopharmacology, 2022, 296, 115456.	2.0	2
986	The Dendritic Cell Dilemma in the Skin: Between Tolerance and Immunity. Frontiers in Immunology, 0, 13, .	2.2	7
988	Increased risk of olfactory and taste dysfunction in the United States psoriasis population. European Archives of Oto-Rhino-Laryngology, 0, , .	0.8	0
989	Dynamic trafficking patterns of IL-17-producing $\hat{I}^3\hat{I}$ T cells are linked to the recurrence of skin inflammation in psoriasis-like dermatitis. EBioMedicine, 2022, 82, 104136.	2.7	14
990	Inverse correlation between the expression of AMPK/SIRT1 and NAMPT in psoriatic skin: A pilot study. Advances in Medical Sciences, 2022, 67, 262-268.	0.9	4
991	Topical formulation based on disease-specific nanoparticles for single-dose cure of psoriasis. Journal of Controlled Release, 2022, 349, 354-366.	4.8	12
992	SerpinB7 deficiency contributes to development of psoriasis via calcium-mediated keratinocyte differentiation dysfunction. Cell Death and Disease, 2022, 13, .	2.7	6
993	Therapeutic Potentials of Secoiridoids from the Fruits of Ligustrum lucidum Aiton against Inflammation-Related Skin Diseases. Pharmaceuticals, 2022, 15, 932.	1.7	3
994	Calcium/calmodulin-dependent protein kinase IV promotes imiquimod-induced psoriatic inflammation via macrophages and keratinocytes in mice. Nature Communications, 2022, 13, .	5.8	19
995	A sharp decrease of Th17, CXCR3+-Th17, and Th17.1 in peripheral blood is associated with an early anti-IL-17-mediated clinical remission in psoriasis. Clinical and Experimental Immunology, 2022, 210, 79-89.	1.1	4
996	Contribution of the Environment, Epigenetic Mechanisms and Non-Coding RNAs in Psoriasis. Biomedicines, 2022, 10, 1934.	1.4	4
997	Psoriatic Dermal-Derived Mesenchymal Stem Cells Induced C3 Expression in Keratinocytes. Clinical, Cosmetic and Investigational Dermatology, 0, Volume 15, 1489-1497.	0.8	2
998	Single-cell immune ecosystem and metabolism reprogramming imprinted by psoriasis niche. Annals of Translational Medicine, 2022, 10, 837-837.	0.7	2
999	Role of cyclosporine (CsA) in immuno-dermatological conditions. Indian Dermatology Online Journal, 2022, 13, 585.	0.2	2
1000	Microorganisms in Pathogenesis and Management of Vitiligo. , 2022, , 189-223.		1
1001	Taurine and N-Bromotaurine in Topical Treatment of Psoriasis. Advances in Experimental Medicine and Biology, 2022, , 99-111.	0.8	2
1002	Expression of B lymphocyte-induced maturation protein 1 (Blimp-1) in keratinocyte and cytokine signalling drives human Th17 response in psoriasis. Archives of Dermatological Research, 2023, 315, 481-490.	1.1	1

#	Article	IF	CITATIONS
1003	An Update on Photodynamic Therapy of Psoriasisâ€"Current Strategies and Nanotechnology as a Future Perspective. International Journal of Molecular Sciences, 2022, 23, 9845.	1.8	8
1004	Efficacy and safety of curcumin in psoriasis: preclinical and clinical evidence and possible mechanisms. Frontiers in Pharmacology, 0, 13, .	1.6	7
1005	Skin neuropathy and immunomodulation in diseases. Fundamental Research, 2024, 4, 218-225.	1.6	1
1006	Skin microbiota analysis in patients with anorexia nervosa and healthy-weight controls reveals microbial indicators of healthy weight and associations with the antimicrobial peptide psoriasin. Scientific Reports, 2022, 12, .	1.6	2
1007	A role for whey acidic protein four-disulfide-core 12 (WFDC12) in the pathogenesis and development of psoriasis disease. Frontiers in Immunology, 0 , 13 , .	2.2	1
1008	Gene Profiling of a 3D Psoriatic Skin Model Enriched in T Cells: Downregulation of PTPRM Promotes Keratinocyte Proliferation through Excessive ERK1/2 Signaling. Cells, 2022, 11, 2904.	1.8	3
1009	Types of Psoriasis and Their Effects on the Immune System. Cureus, 2022, , .	0.2	3
1010	Lack of association between SOCS3 and SOCS7 polymorphisms and psoriasis. Immunity, Inflammation and Disease, 2022, 10, .	1.3	2
1011	Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion. Expert Review of Clinical Immunology, 2022, 18, 1033-1047.	1.3	20
1012	Efficacy and safety of apremilast and phototherapy versus phototherapy only in psoriasis vulgaris. Journal of Dermatology, 2022, 49, 1211-1220.	0.6	3
1013	Individualised computational modelling of immune mediated disease onset, flare and clearance in psoriasis. PLoS Computational Biology, 2022, 18, e1010267.	1.5	2
1014	Retinal vascular assessment in psoriatic patients with and without metabolic syndrome using optical coherence tomography angiography. Scientific Reports, 2022, 12, .	1.6	0
1015	Role of Pro-inflammatory and Anti-inflammatory Cytokines in Pathophysiology of Psoriasis. Current Oral Health Reports, 2022, 9, 132-145.	0.5	2
1016	Pathogenesis, multi-omics research, and clinical treatment of psoriasis. Journal of Autoimmunity, 2022, 133, 102916.	3.0	21
1017	Psoriasis with special reference to Unani medicine – A review. Open Health, 2022, 3, 124-140.	0.4	0
1018	ARG1 and CXCL2 are potential biomarkers target for psoriasis patients. Molecular Pain, 2022, 18, 174480692211284.	1.0	1
1019	Psoriasis, An Overview of its Pathogenesis and Available Treatment Modalities., 2022, 2022, 1-5.		0
1020	Up-regulation of BTN3A1 on CD14 $<$ sup>+ $<$ /sup> cells promotes $V\hat{I}^39V\hat{I}^2$ T cell activation in psoriasis. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	7

#	Article	IF	CITATIONS
1021	IL-17D-induced inhibition of DDX5 expression in keratinocytes amplifies IL-36R-mediated skin inflammation. Nature Immunology, 2022, 23, 1577-1587.	7.0	16
1022	Topical Tirbanibulin, a Dual Src Kinase and Tubulin Polymerization Inhibitor, for the Treatment of Plaque-Type Psoriasis: Phase I Results. Pharmaceutics, 2022, 14, 2159.	2.0	1
1024	Advances in the modulation of ROS and transdermal administration for anti-psoriatic nanotherapies. Journal of Nanobiotechnology, 2022, 20, .	4.2	3
1025	Single-Cell RNA Sequencing Reveals the Immune Cell Profiling in IMQ Induced Psoriasis-Like Model. Journal of Inflammation Research, 0, Volume 15, 5999-6012.	1.6	2
1026	Association of PSORS1C3, CARD14 and TLR4 genotypes and haplotypes with psoriasis susceptibility. Genetics and Molecular Biology, 2022, 45, .	0.6	1
1027	Advancing Science: Driving Progress Today for a Clearer Tomorrow. EMJ Dermatology, 0, , 44-52.	0.0	0
1028	Hyaluronic Acid Nanoparticles as a Topical Agent for Treating Psoriasis. ACS Nano, 2022, 16, 20057-20074.	7. 3	11
1029	<scp>CCN1</scp> upregulates <scp>IL</scp> â€36 via <scp>AKT</scp> / <scp>NFâ€Î°B</scp> and <scp>ERK</scp> / <scp>CEBP β</scp> â€mediated signaling pathways in psoriasisâ€like models. Journal of Dermatology, 2023, 50, 337-348.	0.6	3
1030	A Review of the Safety of Interleukin-17A Inhibitor Secukinumab. Pharmaceuticals, 2022, 15, 1365.	1.7	13
1031	Tryptanthrin ameliorates imiquimod-induced psoriasis in mice by suppressing inflammation and oxidative stress via NF-κB/MAPK/Nrf2 pathways. Journal of Natural Medicines, 2023, 77, 188-201.	1.1	3
1032	A novel hyaluronic acid-based dissolving microneedle patch loaded with ginsenoside Rg3 liposome for effectively alleviate psoriasis. Materials and Design, 2022, 224, 111363.	3.3	11
1033	Systemic Immune Inflammatory Index Is Associated with Pustular Psoriasis: A Single Center Retrospective Study. Journal of Cosmetics Dermatological Sciences and Applications, 2022, 12, 174-186.	0.1	0
1035	Kaempferol modulates IFN-γ induced JAK-STAT signaling pathway and ameliorates imiquimod-induced psoriasis-like skin lesions. International Immunopharmacology, 2023, 114, 109585.	1.7	7
1037	Mechanisms and Effects of Isorhamnetin on Imiquimod-Induced Psoriasiform Dermatitis in Mice. Life, 2022, 12, 2107.	1.1	1
1038	Serum calprotectin: a new potential biomarker for psoriasis?. Minerva Medica, 2022, 113, .	0.3	0
1039	Immunity: Psoriasis comorbid with atherosclerosis. Frontiers in Immunology, 0, 13, .	2.2	5
1041	UBE2L3 Reduces TRIM21 Expression and IL- $1\hat{1}^2$ Secretion in Epidermal Keratinocytes and Improves Psoriasis-Like Skin. Journal of Investigative Dermatology, 2023, 143, 822-831.e4.	0.3	3
1042	Advances in pathogenesis and nanoparticles (NPs)-mediated treatment of psoriasis. Frontiers in Immunology, 0, 13, .	2.2	4

#	Article	IF	CITATIONS
1043	Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway. Journal of Cutaneous Medicine and Surgery, 2023, 27, 3S-24S.	0.6	8
1044	Genome-wide DNA methylation of Munroâ \in ^{Ms} microabscess reveals the epigenetic regulation in the pathogenesis of psoriasis. Frontiers in Immunology, 0, 13, .	2.2	3
1045	An optical system for noninvasive microscopy of psoriatic mice in vivo. Journal of Biophotonics, 2023, 16, .	1.1	0
1046	The Human Dermis as a Target of Nanoparticles for Treating Skin Conditions. Pharmaceutics, 2023, 15, 10.	2.0	6
1048	Genetic analysis of potential biomarkers and therapeutic targets in ferroptosis from psoriasis. Frontiers in Immunology, 0, 13, .	2.2	3
1049	Single-cell analysis reveals melanocytes may promote inflammation in chronic wounds through cathepsin G. Frontiers in Genetics, $0,14,.$	1.1	1
1050	Increased expression of ELOVL7 contributes to production of inflammatory cytokines in THP-1 cell-derived M1-like macrophages. Journal of Clinical Biochemistry and Nutrition, 2023, , .	0.6	1
1051	Anti-inflammatory effect of taxifolin in TNF- \hat{l} ±/IL-17A/IFN- \hat{l} 3 induced HaCaT human keratinocytes. Applied Biological Chemistry, 2023, 66, .	0.7	2
1052	Potential skin health promoting benefits of costunolide: a therapeutic strategy to improve skin inflammation in imiquimod-induced psoriasis. Food and Function, 2023, 14, 2392-2403.	2.1	3
1053	Immune-Epithelial Cross Talk in Regeneration and Repair. Annual Review of Immunology, 2023, 41, 207-228.	9.5	11
1054	Intestinal dysbiosis exacerbates the pathogenesis of psoriasis-like phenotype through changes in fatty acid metabolism. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	15
1055	Dietary inflammatory potential and psoriasis: A crossâ€sectional study. Journal of Dermatology, 2023, 50, 692-699.	0.6	2
1056	FXYD3 enhances IL-17A signaling to promote psoriasis by competitively binding TRAF3 in keratinocytes. , 2023, 20, 292-304.		4
1057	Potential Antioxidant Enzymes from Fungi and Their Clinical Significance. , 2023, , 147-177.		0
1058	Preclinical study models of psoriasis: State-of-the-art techniques for testing pharmaceutical products in animal and nonanimal models. International Immunopharmacology, 2023, 117, 109945.	1.7	3
1059	Nerve growth factor mediates activation of transient receptor potential vanilloid 1 in neurogenic pruritus of psoriasis. International Immunopharmacology, 2023, 118 , 110063 .	1.7	5
1060	Alleviation of imiquimod-induced psoriasis-like symptoms in Ror \hat{l}_{\pm} -deficient mouse skin. BMB Reports, 2023, , .	1.1	2
1061	Skin Diseases and Tryptophan Metabolism. Journal of the Society of Japanese Women Scientists, 2023, 23, 8-15.	0.0	0

#	Article	IF	CITATIONS
1062	The Aetiopathogenesis of Psoriasis in 2014: An Update. EMJ Dermatology, 0, , 61-70.	0.0	0
1063	Evaluation of the Efficacy of Xyloglucan, Pea Protein and Opuntia ficus-indica Extract in a Preclinical Model of Psoriasis. International Journal of Molecular Sciences, 2023, 24, 3122.	1.8	1
1064	The therapeutic effect of tacrolimus in a mouse psoriatic model is associated with the induction of myeloid-derived suppressor cells. Rheumatology and Immunology Research, 2022, 3, 190-197.	0.2	1
1065	Identification of the BTN3A3 Gene as a Molecule Implicated in Generalized Pustular Psoriasis in a Chinese Population. Journal of Investigative Dermatology, 2023, 143, 1439-1448.e21.	0.3	4
1066	Therapeutic effects of mesenchymal stem cells and their derivatives in common skin inflammatory diseases: Atopic dermatitis and psoriasis. Frontiers in Immunology, 0, 14, .	2.2	3
1067	The Experimental Animal Models in Psoriasis Research: A Comprehensive Review. International Immunopharmacology, 2023, 117, 109897.	1.7	1
1068	Topical Diacerein Decreases Skin and Splenic CD11c+ Dendritic Cells in Psoriasis. International Journal of Molecular Sciences, 2023, 24, 4324.	1.8	0
1069	The SELP, CD93, IL2RG, and VAV1 Genes Associated with Atherosclerosis May Be Potential Diagnostic Biomarkers for Psoriasis. Journal of Inflammation Research, 0, Volume 16, 827-843.	1.6	2
1070	PD-L1 Enhanced by cis-Urocanic Acid on Langerhans Cells Inhibits $V\hat{l}^34+\hat{l}^3\hat{l}$ T17 Cells in Imiquimod-Induced Skin Inflammation. Journal of Investigative Dermatology, 2023, 143, 1449-1460.	0.3	3
1071	Metabolic rewiring in keratinocytes by miRâ€31â€5p identifies therapeutic intervention for psoriasis. EMBO Molecular Medicine, 2023, 15, .	3.3	4
1072	Inducible nitric oxide synthase-expressing myeloid-derived suppressor cells regulated by interleukin 35 contribute to the pathogenesis of psoriasis. Frontiers in Immunology, 0, 14, .	2.2	2
1073	The Chemokine, CCL20, and Its Receptor, CCR6, in the Pathogenesis and Treatment of Psoriasis and Psoriatic Arthritis, O, , 247553032311591.	0.3	0
1074	Zonula occludensâ€1 distribution and barrier functions are affected by epithelial proliferation and turnover rates. Cell Proliferation, 2023, 56, .	2.4	6
1075	Cornus officinalis Seed Extract Inhibits AIM2-Inflammasome Activation and Attenuates Imiquimod-Induced Psoriasis-like Skin Inflammation. International Journal of Molecular Sciences, 2023, 24, 5653.	1.8	2
1076	SERPINB4 Promotes Keratinocyte Inflammation via p38MAPK Signaling Pathway. Journal of Immunology Research, 2023, 2023, 1-9.	0.9	2
1077	Exploration of the relationship between periodontal disease and skin disease in honor of Gum Day. Journal of Periodontal and Implant Science, 2023, 53, 97.	0.9	0
1078	IL17A Blockade with Ixekizumab Suppresses MuvB Signaling in Clinical Psoriasis. Journal of Investigative Dermatology, 2023, 143, 1689-1699.	0.3	3
1079	Identification of novel immune subtypes and potential hub genes of patients with psoriasis. Journal of Translational Medicine, 2023, 21, .	1.8	0

#	Article	IF	CITATIONS
1080	Elucidating the NB-UVB mechanism by comparing transcriptome alteration on the edge and center of psoriatic plaques. Scientific Reports, $2023,13,.$	1.6	2
1081	Bone marrow derived mesenchymal stem cells therapy for rheumatoid arthritis - a concise review of past ten years. Molecular Biology Reports, 0, , .	1.0	1
1082	Translation-dependent skin hyperplasia is promoted by type $1/17$ inflammation in psoriasis. Journal of Dermatological Science, 2023, 110 , $10-18$.	1.0	2
1083	Diosmin nanocrystal gel alleviates imiquimod-induced psoriasis in rats via modulating TLR7,8/NF-κB/micro RNA-31, AKT/mTOR/P70S6K milieu, and Tregs/Th17 balance. Inflammopharmacology, 2023, 31, 1341-1359.	1.9	2
1084	Identification immune response genes in psoriasis after treatment with secukinumab. BMC Medical Genomics, 2023, 16 , .	0.7	0
1085	Building an infrastructure to support the development, conduct, and reporting of informative clinical studies: The Rockefeller University experience. Journal of Clinical and Translational Science, 2023, 7, .	0.3	1
1086	Protein Kinase CK2 Promotes Proliferation, Abnormal Differentiation, and Proinflammatory Cytokine Production of Keratinocytes via Regulation of STAT3 and Akt Pathways in Psoriasis. American Journal of Pathology, 2023, 193, 567-578.	1.9	1
1087	Effects of pulsed dye laser treatment in psoriasis: A nerveâ€wrecking process?. Experimental Dermatology, 2023, 32, 1165-1173.	1.4	0
1093	Deep Learning-Based Skin Disease Detection Using Convolutional Neural Networks (CNN). Lecture Notes in Electrical Engineering, 2023, , 551-564.	0.3	5
1103	Emerging trends in combination strategies with phototherapy in advanced psoriasis management. Inflammopharmacology, 2023, 31, 1761-1778.	1.9	3
1143	Modulation of oxidative stress in psoriasis: Pathophysiology and therapy., 2023,, 255-278.		0
1148	Stress in psoriasis., 2024,, 77-81.		0
1150	Recent Trends in Topical Herbal Nanotherapeutics for Psoriasis., 2023,, 559-580.		0
1171	The Use of Microbial Modifying Therapies to Prevent Psoriasis Exacerbation and Associated Cardiovascular Comorbidity. Inflammation, 0, , .	1.7	1
1216	Comparison of Machine Learning Classifiers on Integrated Transcriptomic Data., 2023,,.		0
1228	Exploring the potential of Toxoplasma gondii in drug development and as a delivery system. Experimental and Molecular Medicine, 2024, 56, 289-300.	3.2	0
1229	Pathogenesis, molecular mechanism and treatment approaches of psoriasis: An update. AIP Conference Proceedings, 2024, , .	0.3	0